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Abstract 
GABAA receptors are chloride ion channels composed of five subunits, mediat-
ing fast synaptic and tonic inhibition in the mammalian brain. 19 different subunit 
isoforms have been identified, with the major receptor type in mammalian adult brain 
consisting of α1, β2, and γ2 subunits. GABAA receptors are the target of numerous se-
dating and anxiolytic drugs such as benzodiazepines. The currently known endoge-
nous ligands are GABA, neurosteroids and the endocannabinoid 2-arachidonoyl glyc-
erol (2-AG). The pharmacological properties of this chloride ion channel strictly depend 
on receptor subunit composition and arrangement. GABAA receptors bind and are in-
hibited by epileptogenic agents such as picrotoxin, and cyclodiene insecticides such as 
dieldrin. We screened aromatic monovalent anions with five-fold symmetry for inhibition 
of GABAA receptors. One of the anions, PCCP- inhibited currents elicited by GABA with 
comparable potency as picrotoxin. This inhibition showed all characteristics of an open 
channel block. The GABAA receptor ion channel is lined by residues from the M2 
membrane-spanning segment. To identify important residues of the pore involved in 
the interaction with the blocking molecules PCCP-, a mutation scan was performed in 
combination with subsequent analysis of the expressed mutant proteins using electro-
physiological techniques. 
In a second project we characterised a light-switchable modulator of GABAA re-
ceptors based on propofol. It was my responsibility to investigate the switching kinetics 
in patch clamp experiments. After its discovery in 1980, propofol has become the most 
widely used intravenous general anaesthetic. It is commonly accepted that the anaes-
thesia induced by this unusually lipophilic drug mostly results from potentiation of 
GABA induced currents. While GABAA receptors respond to a variety of ligands, they 
are normally not sensitive towards light. This light sensitivity could be indirectly 
achieved by using modulators that can be optically switched between an active and an 
inactive form. We tested an azobenzene derivative of propofol where an aryldiazene 
unit is directly coupled to the pharmacophore. This molecule was termed azopropofol 
(AP2). The effect of AP2 on Cl- currents was investigated with electrophysiological 
techniques using α1β2γ2 GABAA receptors expressed in Xenopus oocytes and HEK-
cells.  
In the third project we wanted to investigate the functional role of GABAA recep-
tors in the liver, and their possible involvement in cell proliferation. GABAA receptors 
are also found in a wide range of peripheral tissues, including parts of the peripheral 
nervous system and non-neural tissues such as smooth muscle, the female reproduc-
tive system, liver and several cancer tissues. However their precise function in non 
neuronal or cancerous cells is still unknown. For this purpose we investigated expres-
sion, localization and function of the hepatocytes GABAA receptors in model cell lines 
and healthy and cancerous hepatocytes. 
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1 Introduction 
1.1 Central nervous system 
The nervous system can be divided into two parts: The central nervous system 
(CNS) is the part of the nervous system consisting of the brain and spinal cord. It is 
opposed to the peripheral nervous system  (PNS), which is composed of nerves lead-
ing to and from the CNS throughout the rest of the body. The nervous system sends 
and receives information from all parts of the body, regulating internal organ function 
and responding to changes in the external environment. 
The human body is made up of trillions of cells. The human brain has approxi-
mately 86 billion neurons (Azevedo et al., 2009) and the rest is formed by three differ-
ent types of non neuronal cells called glia cells. The main functions of the glia cells are 
to support and provide nutriments and oxygen for the neurons, to control the communi-
cation between neurons at the synapsis; they are also responsible of the immune re-
sponse, cleaning up the CNS from damaged neurons and infectious agents. (Allen and 
Barres, 2009; Araque and Navarrete, 2010). A typical neuron, different from the other 
cells, has specialized cell parts called dendrites and axon, which enable them to send 
and receive information. Dendrites bring electrical signals to the cell body and axons 
take information away from the cell body. Neuronal signalling actually involves both 
electrical and chemical or processes. Communication between neurons is achieved at 
synapses and it is called neurotransmission. To achieve long distance and rapid com-
munication, neurons have evolved special abilities for sending electrical signals along 
axons in the form of an action potential (Figure 1). The neuron has a resting potential 
around -70 mV with the inside of the neuron negatively charged relative to the outside 
the cell. The resting potential of the neuron refers to the difference between the voltage 
inside and outside the neuron. The plasma membrane of a neuron contains voltage-
gated cation channels, which are responsible for generating the action potentials. 
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Figure 1. Neuronal signalling. (figure taken from Elliott , 2012.) 
 
A stimulus sent out from a cell body, that causes sufficient depolarization 
promptly opens the voltage-gated Na+ channels, allowing Na+ ions to enter the cell 
down their electrochemical gradient causing a depolarization of the membrane. Once 
the cell reaches a certain threshold, an action potential will fire, sending the electrical 
signal down the axon. After the neuron has fired the potassium channels open, allow-
ing flow of K+ ions inside the cell and the sodium channels close, gradually returning 
the neuron to its resting potential, this is called “refractory period” in which another ac-
tion potential is not possible. In myelinated axons, the sodium channels are present 
only at the nodes of Ranvier, the only place where the signal can be propagate along 
the excitable axon (Figure 2). The axonal membrane will be depolarized from one 
node to the other; this form of impulse propagation is called saltatory conduction. Such 
movement of the wave of depolarization is much more rapid than in unmyelinated fi-
bers. 
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Figure 2. Representation of the propagation of an action potential along the ax-
on. (figure taken from Thomson Learning, 2001). 
1.1.1 Excitatory and inhibitory synapses 
The contacts between the dendrites of one neuron with other neurons are 
termed synapses. Each neuron forms thousands of synapses with other neurons or 
other types of cells. In almost all the synapses, transmission is in one direction from the 
first (or presynaptic) neuron to the second or (postsynaptic) neurons. An arriving action 
potential depolarizes the pre-synaptic neuron and opens voltage-dependent calcium 
channels. The influx of calcium ions increases the calcium concentration in the pre-
synaptic terminal, which in turn leads the vesicle containing the neurotransmitters to 
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fuse with the plasma membrane and release the neurotransmitters into the synaptic 
cleft. The small volume of the cleft allows neurotransmitter concentration to be raised 
and lowered rapidly. In order to have any effect on the postsynaptic cell, a neurotrans-
mitter molecule must fit onto a receptor precisely as there are specific receptors for 
specific neurotransmitters.  
There are two major types of neurotransmitter receptors. The first type con-
sistes of ion channels. These receptors opens after binding of neurotransmitter mole-
cules and act in the millisecond time range (fast neurotransmission). The second type 
consistes of G-protein coupled receptors. These are coupled to second messenger 
system and act in the 100 milliseconds time range (slow neurotransmission). Most neu-
rotransmitters interact primarily with post-synaptic receptors, but there are also pre-
synaptic receptors, which provide fine control of neurotransmitter release by a negative 
feedback mechanism. 
 In the fast neurotransmission when a neurotransmitter binds to a receptor and 
leads to the opening of the integral ion channel, which results in a change in the mem-
brane potential of a postsynaptic cell. Synaptic activation of inhibitory or excitatory neu-
rotransmitter receptors respectively generate an inhibitory postsynaptic potential (IP-
SPs) or excitatory postsynaptic potentials (EPSPs). The most common inhibitory neu-
rotransmitters in the nervous system are γ-aminobutyric acid (GABA) and glycine; the 
most abundant excitatory neurotransmitters are glutamate or acetylcholine. 
A postsynaptic potential is termed as inhibitory when the resulting change in 
membrane voltage makes it more difficult for the cell to fire an action potential, lowering 
the firing rate of the neuron. They are the opposite of excitatory postsynaptic potentials, 
which result from the flow of ions like sodium into the cell because the opening of 
postsynaptic cation channels depolarizes the postsynaptic nerve terminal and trigger a 
new action potential in the post-synaptic cell. 
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1.2 GABAergic neurotransmission 
1.2.1 Biosynthesis and metabolism of GABA 
γ-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the central 
nervous system of mammals (Curtis et al., 1995; Mekarnan and Whithing, 1996; 
Krnjevic, 1997). About 20–50% of all synapses utilize this neurotransmitter (Barnard et 
al., 1998; Mehta and Ticku, 1999). Figure 3 summarizes synthesis, release, and 
reuptake of GABA. 
Two different forms of the enzyme glutamic acid decarboxylase (GAD) (GAD65 
and GAD67) catalyse the decarboxylation of glutamate to GABA at the synaptic termi-
nals. Most of the GABA and glutamate derive from the reserves of glutamine present in 
the glial cells. The main source of glutamine and glutamic acid, and then GABA, is glu-
cose: in fact, in the Krebs cycle one of the products of the glucose metabolism is the α-
ketoglutaric acid, which is converted to L-glutamic acid by the enzyme transaminase. 
After the synthesis, GABA neurotransmitter is transported to the synaptic vesicles 
through a vesicular neurotransmitter transporter (VGAT) and released by a calcium-
dependent exocytosis mechanism. 
The physiological effect by GABA is mediated by the action of GABA on iono-
tropic or metabotropic receptors, located in the pre- and post-synaptic terminals. The 
synaptic action of GABA is terminated by the action of the reuptake proteins of the neu-
rotransmitter (GATs), which are located in the cytoplasmic membranes of the nerve 
terminals and in the surrounding glial cells (astrocytes). GABA-transaminase present in 
the mitochondria of the glial cells and neurons, catalyses the conversion of GABA into 
succinic semialdehyde and glutamate. Succinic semialdehyde is then oxidised into 
succinic acid by succinic semialdehyde dehydrogenase and as such enters the citric 
acid cycle as a usable source of energy.  
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Figure 3. Schematic representation of the synthesis, release, and reuptake of the 
inhibitory neurotransmitter GABA. (figure taken from Purves D. et al. 2001). 
 
It is estimated that more than 90% of all GABA in the mammalian CNS is degraded in 
this way and contributes to energy metabolism in the citric acid cycle. 
The GABAergic function is finely regulated at multiple levels (Cherubini and 
Conti, 2001) which includes the synthesis of the neurotransmitter from the two isoforms 
of the glutamic acid carboxylase (GAD) (Erlander et al., 1991; Esclapez et al., 1994; 
Soghomonian and Martin, 1998); by the regulation of vesicular transporter which would 
be responsible for the storage of GABA in the synaptic vesicle and subsequent release 
at GABA synapses (Dumoulin et al., 1999; Gasnier, 2000), by the release of Ca2+ (Wall 
and Usowicz, 1997; Vautrin et al., 2000; Kirischuk et al., 2002), by reuptake into neu-
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rons and glial cells (Borden, 1996; Quick et al., 1997) and the activation of multiple 
receptors located pre-, post-, and extra-synaptically. 
1.3 GABA receptors 
1.3.1 Classification 
GABA is capable of interacting with two major subtypes of specific receptors: 
ionotropic GABAA receptors (Barnard et al., 1998) and metabotropic GABAB receptors 
(Bowery et al., 2002) (Figure 4), which are expressed ubiquitously in the CNS. There is 
also another subclass of GABAA receptors, associated to ρ subunit, almost exclusively 
expressed in the retina (Bormann and Feingespan, 1995; Kusama et al., 1995; Chebib 
et al., 1997), previously known as the GABAC receptor. However since GABAС recep-
tors are closely related in sequence, structure, and function to GABAA receptors the 
nomenclature committee of the IUPHAR has recommended that the use of GABAС 
name should be abandoned and these ρ receptors should be designated as the ρ sub-
family of the GABAA receptors (Barnard et al., 1998; Olsen and Sieghart, 2008).  
 
 
Figure 4. Schematic representation of the different subtypes of the GABA recep-
tor. A) GABAA receptor, B) GABAB receptor. 
A) GABAA receptor B) GABAB receptor 
α  α  
β  
γ  β  
 
GABABR1 
G 
GABABR2 
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1.3.2 GABAA Receptors 
GABAA receptors belong to the family of cys-loop receptors characterized by a 
disulphide bond between two cysteine residues in the extracellular domain. This family 
consists of the nicotinic acetylcholine receptors, the GABAA and the 5-HT3 receptors, 
the glycine receptors and some bacterial receptors (Macdonald and Olsen, 1994; Dunn 
et al., 1994; Rabow et al., 1995; Barnard et al., 1998; Hervers and Luddens, 1998; Enz, 
2001; Sieghart and Sperk, 2002; Chebib, 2004; Gibbs and Johnston, 2005). 
GABAA receptors are heterooligomeric receptors, constituted by the assembly 
of five different or identical subunits that form an ion channel permeable to chloride 
ions (Macdonald and Olsen, 1994; Sieghart, 1995; Sieghart and Sperk, 2002; Sigel and 
Steinmann, 2012) (Figure 5). 
They are activated by two molecules of GABA interacting on their specific sites. 
The binding of GABA to the receptor leads to a rapid opening of the ion channel asso-
ciated to the protein, through which chloride ions flow according to their electrochemi-
cal gradient. An increased neuronal chloride conductance leads to a reduction of the 
probability that an action potential can be initiated in this cell. GABAA receptors mediate 
fast synaptic inhibition but in few cases, these receptors have been reported to act ex-
citatory, for example during nervous system development (Ben-Ari et al., 1997; Taketo 
and Yoshioka, 2000) or in certain cell populations (cells of pituitary pars intermedia, loci 
in embryonic and early postnatal life in the mammal, SP-O interneurons in the rat hip-
pocampal CA3 area) (Tomiko et al., 1983; Cherubini et al., 1991; Ben-Ari et al., 1997; 
Lamsa and Taira, 2003). This exceptional phenomenon is a consequence of high inter-
nal Cl- concentration in these neurons. 
Due to their wide distribution within the nervous system of mammals, the 
GABAA receptors play a role in virtually all brain functions. The highest GABAA receptor 
densities are found in the brain cortex, followed by the hypothalamus, cerebellum, hip-
pocampus and striatum (Braestrup et al., 1977; Fritschy and Möhler, 1995; McKernan 
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and Whiting, 1996; Bateson, 2004). Receptor populations are also found in midbrain, 
medulla oblongatapons and spinal cord (Fritschy and Möhler, 1995; Bateson, 2004). As 
mentioned below, GABAA receptors can also be found, but in a limited amount, in non-
neural tissues such as the pancreas, placenta, immune cells, liver, bone growth plates 
and several other endocrine tissue (Minuk et al., 2007) where their functional roles are 
still under study and their pharmacological relevance remains to be established. 
 
 
Figure 5. Schematic representation of the three-dimensional structure of the 
GABAA receptor. Five receptor subunits (2α, 2β, 1γ)  are indicated immersed in the 
lipid bilayer of the cell membrane, delimiting a central ion channel permeable to the ion 
Cl-. (figure taken from Jacob et al., 2008). 
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GABAA receptors formed by ρ subunit are located primarily in the retina and 
they are expressed on the cell membrane of the bipolar cells. They differ from GABAA 
and GABAB receptors as insensitive to both bicuculline and baclofen, but they are very 
sensitive to blockade of picrotoxin similar to GABAA receptors. They are formed by five 
ρ subunits and are therefore called homomeric receptors (Bormann, 2000). 
1.3.3 GABAB receptors 
Another class of GABA receptors are GABAB receptors. These receptors are 
heterodimers composed of two related subunits, GABAB R1 and GABAB R2 (Kaupmann 
et al., 1997; Bowery et al., 2002). The GABAB G-protein coupled receptors are activat-
ed selectively by GABA and his derivative, β-p-chlorophenyl GABA (baclofen) and, 
unlike GABAA receptors, are insensitive to bicuculline and muscimol. Other members of 
the G-protein coupled receptors are the metabotropic glutamate receptors, the musca-
rinic acetylcholine receptor and receptors for the dopamine, norepinephrine, histamine, 
and serotonin. They are protein complexes that span the cell membrane. Receptors 
coupled to a second messenger consist of three parts: the extracellular part, where 
glycosylation occurs; the transmembrane part, which forms a pocket where the neuro-
transmitter is presumed to act; and the intracytoplasmic part, where G-protein binding 
occurs. Occupation of such receptors alters the level of second messenger molecules 
that in turn affect among other targets ion channels (Figure 6).  
The inhibitory effects of GABAB receptors on neuronal activity are mediated by 
decreased neurotransmitter release via inhibition of N/P/Q-type Ca2+ channels and by 
postsynaptic hyperpolarisation via the activation of GIRK channels (also known as in-
wardly rectifying K+ Kir3 channels) by Gβγ dimer (Mott and Lewis, 1994; Takahashi et 
al., 1998; Couve et al., 2000). So the main function of the receptors GABAB at presyn-
aptic level is that of self-regulate the release of GABA when concentrations become 
excessively high in the synaptic cleft.  
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Figure 6. Structure of the GABAB receptor. (figure taken from University of Zurich, 
2010 Impressum) 
Because postsynaptic GABAB receptors are located at extrasynaptic sites away 
from GABA release sites, their activation is limited by GABA uptake and requires pat-
terns of presynaptic activity that lead to GABA spillover and elevations of ambient 
GABA (Scanziani, 2000; Kulik et al., 2003). Under conditions of increased ambient 
GABA, such as occur with ischemia, epileptic seizures, or drugs that increase GABA 
concentration, coactivation of GABAA receptors and postsynaptic GABAB receptors will 
occur (Scanziani et al.,1991; During and Spencer, 1993; Wu et al., 2003). Postsynaptic 
GABAB receptors open G protein-activated inwardly rectifying potassium channels 
(GIRKs), which inhibit neuronal activity by local shunting and generate slow (100–500 
ms) inhibitory postsynaptic potentials (IPSPs) that hyperpolarize the membrane 
(Gassmann and Bettler, 2012). 
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1.3.4 GABAA subunit composition 
Initially, two subunits of a GABAA receptor have been purified from bovine brain 
using affinity chromatography (α, β) (Sigel et al., 1983; Sigel and Barnard, 1984). Sub-
sequently the cDNAs coding for these subunits have been cloned (Schofield et al., 
1987). Application of molecular biology techniques has allowed the cloning of different 
types of subunits (α1-6, β1-3, γ1-3, θ, ε, δ, π and ρ1-3) (Barnard et al., 1998; Whiting, 1999) 
(Figure 7). 
The purification of the receptor protein also provided the opportunity to raise 
monoclonal antibodies to the receptor, which were used to study the fine anatomical 
detail of receptor distribution.  
 
  
Figure 7. GABAA receptor subunits. 
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 The GABAA receptor subunits are up to 450 amino acids residues in length and 
each of these has an amino terminal extracellular domain, four hydrophobic trans 
membrane domains (TM1 - TM4) forming a α helices (Schofield et al., 1987; Olsen and 
Tobin, 1990; Macdonald and Olsen, 1994; Hervers and Luddens, 1998), and a long 
intracellular loop between TM3 and TM4 containing specific sites for phosphorylation 
by Ser/Thr and Tyr dependent kinases (Mehta and Ticku, 1999) (Figure 8). Binding 
sites for the agonist GABA and for modulators of the benzodiazepine type are located 
in the N-terminal extra-cellular domain.  
Based on the analogy to the nAChR, it is suggested that the N-terminal extra-
cellular domain is built up by a 10-fold β-strand containing one α-helix. The transmem-
brane helix M2 of each subunit contributes to the central pore, while helices M1, M3 
and M4 form an outer shell to shield M2 from the lipids (Unwin, 2005). Recent crystalli-
zation of a human homomeric β3 receptors has confirmed this picture (Miller and 
Aricescu, 2014). 
 
 
Figure 8. Topology of a subunit and the assembly of subunits. (figure taken from 
http://en.wikipedia.org/wiki/GABAA_receptor). 
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The different subunits have about 30-40% homology in their amino acid se-
quence and approximately 70% sequence homology between the subunit isoforms 
within a family (Figure 9) (Barnard et al., 1998; Whiting et al., 1999; Bonnert et al., 
1999; Moragues et al., 2000; Bateson, 2004), and they are believed to be derived from 
a single common ancestral gene (Olsen and Tobin, 1990; Schofield et al., 1990; See-
burg et al., 1990; Burt and Kamatchi, 1991; Luddens and Wisden, 1991; Duggan et al., 
1991; Doble and Martin, 1992; Wisden and Seeburg, 1992). 
The different subunit isoforms are encoded by distinct genes localized on differ-
ent chromosomes (Barnard et al., 1998; Whiting et al., 1999; Sieghart and Sperk, 
2002). 
 
 
Figure 9. The subunits of the 
GABAA receptor.  
The dendrogram is constructed 
based on the composition of the 
amino acid sequences of the dif-
ferent subunits of the GABAA re-
ceptor. The length of the seg-
ments that separate the different 
subunits is proportional to the 
evolutionary distance that sepa-
rates their amino acid sequences. 
(figure taken from Sigel and 
Steinmann, 2012). 
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The diversity of receptor subunits is increased by alternative splicing, for example there 
are two forms of the γ2 subunit, γ2S (short) and γ2L (long) (Kofuji et al., 1991; Whiting et 
al., 1990). These splice variants differ by the presence or absence of a short peptide in 
the intracellular loop between TM3 and TM4. Splice variants have also been detected 
for other subunits namely α6, β2, β3, β4 and ρ1 (Sieghart and Sperk, 2002; Barnard et 
al., 1998). The subunits of the GABAA receptors share a high degree of homology with 
other subunits of the same receptor, the subunits of the nicotinic acetylcholine, the gly-
cine and the serotonin (type 3) receptors. All these pentameric receptors share a near 
five-fold symmetry. The degree of symmetry is especially high in the second trans-
membrane domain M2 of these receptors that lines the ion channel. Amino acid resi-
dues of the α1 GABAA receptor subunit, Ala253, Val256, Thr260, Thr261 Leu263, Thr264, 
Thr267, on the second transmembrane domain have been reported to be exposed to the 
channel lumen (Xu and Akabas, 1996). 
The major receptor isoform in mammalian brain consists of α1, β2, and γ2 subu-
nits (Olsen and Sieghart, 2008). Concatenated GABAA receptor subunits studies have 
indicated a 2α:2β:1γ subunit stoichiometry for this receptor (Baumann et al., 2001; 
Baumann et al., 2002; Baur et al., 2006) with a subunit arrangement γβαβα anti-
clockwise as seen from the synaptic cleft (Baumann et al., 2001, Baumann et al., 2002; 
Baur et al., 2006). The presence of a defined subunit stoichiometry and arrangement in 
αβγ receptors indicates that assembly of GABAA receptors proceeds via defined path-
ways. The assembly of subunits seems to occur in the endoplasmic reticulum (ER) and 
to involve interaction with chaperone molecules (Connolly et al., 1996; Bollan et al., 
2003 a,b). For the assembly of GABAA receptors, the chaperones calnexin, immuno-
globulin heavy-chain-binding protein (BiP), and protein disulphide isomerase seem to 
be required.  
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The pharmacological properties depend both on subunit composition (Sigel et 
al., 1990) and arrangement (Minier and Sigel, 2004). It has been determined through 
immunoprecipitation experiments that in a single receptor complex two different 
α subunit isoforms can co-exist (Luddens et al, 1991). From the experimental point of 
view, a considerable number of receptor combinations have been reconstructed in vitro 
in different cell lines (Wong et al., 1992), although immunoprecipitation studies suggest 
that only a limited number of receptor subtypes is expressed in vivo in different neu-
ronal populations (McKernan et al, 1996). 
1.3.5 Synaptic and extrasynaptic GABAA receptors  
Recently it has been shown that distinct subtypes of GABAA receptors are in-
volved in two types of inhibitory control. The transient activation of synaptic GABAA 
receptors (due to the local release of GABA from the presynaptic terminal) is responsi-
ble of the classical "phasic" inhibition, while the persistent activation of GABAA of the 
extra synaptic receptors may generate a form of inhibition called "tonic" (Figure 10). 
 
 
Figure 10. Synaptic and extra-synaptic receptors. The concentration of extracellular 
GABA is regulated by the release mechanisms, diffusion and uptake (recapture). 
GABA can escape from the synaptic cleft (spillover). (figure taken from Hunt et al., 
2013). 
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The receptors that mediate tonic activity are continually exposed to GABA pre-
sent in the extracellular environment ("spill over" of synapses and or released by astro-
cytes) (Nusser and Mody, 2002; Stell and Mody, 2002). These receptors have a very 
high affinity to GABA, and a slow desensitization, compared to receptors located in the 
synaptic space (Wallner et al., 2003). They are activated by very low concentrations of 
GABA (0.5-1 µM) (Mody, 2001) and for a very long time.  
In contrast, the receptors in the synaptic space are activated by very high con-
centrations of GABA (≥ 1mM, close to saturation), directly released into the synaptic 
space and remain open for a very short period of time (≈ 10ms) (Wallner et al., 2003). 
1.3.6 Pharmacological properties of GABAA receptors 
The GABAA receptor is capable of mediating the action of several classes of 
compounds, many of which are of therapeutic importance. GABAA receptors constitute 
a selective target for numerous classes of CNS active drugs, including anxiolytics, sed-
ativo-hypnotics, general anesthetics, anticonvulsants and myo-relaxants. Benzodiaze-
pines, steroids, barbiturates and general anaesthetics are positive modulators, where-
as β-carboline are negative modulators and picrotoxin, dieldrin are non-competitive 
channel blockers (Figure 11).  
The positive modulators bind to allosteric sites on the receptor complex, caus-
ing increased efficiency of the GABA binding site and therefore an increase in Cl- con-
ductance; whereas the negative modulator have an opposed action, they produce an 
allosterically unfavorable conformation for GABA binding and therefore decreasing Cl- 
conductance (Haefely, 1984; Paredes and Agmo, 1992). The non-competitive channel 
blockers bind to or near the central pore of the receptor complex and block Cl- con-
ductance through the ion channel. In order for GABAA receptors to be sensitive to the 
action of benzodiazepines they need to contain an α and a γ subunit, between which 
the benzodiazepine binds (Sigel et al., 2002; Sigel et al., 1998; Sigel and Buhr, 1997). 
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Figure 11. Pharmacology of the GABAA receptor. Schematic of the hypothetical 
molecular structure of the most abundant GABAA receptor composed of α,β and γ sub-
units. On the structure of the receptor complex the recognition sites for different posi-
tive modulators and negative, as well as for the neurotransmitter are indicated. (figure 
adapted from Belelli et al., 2005). 
 
Once bound, the benzodiazepine locks the GABAA receptor in a conformation 
where the neurotransmitter GABA has much higher affinity for the GABAA receptor, 
increasing the frequency of opening of the associated chloride ion channel and hy-
perpolarising the membrane. This potentiates the inhibitory effect of the available 
GABA, leading to sedative and anxiolytic effects.  
1.3.7 Effect of subunit composition on pharmacological properties 
As mentioned in a previous chapter, the pharmacology of the GABAA receptors 
is influenced by its subunit composition and distribution and the receptors mediate two 
fundamentally distinct forms of inhibitory transmission, which depend on their localisa-
tion, either postsynaptic or extrasynaptic. Importantly, these two major populations of 
GABAA receptors are molecularly distinct, with postsynaptic receptors containing mainly 
barbiturate 
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benzodiazepine 
 
 
anaesthetic 
neurosteroids 
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the α1, α2 and α3 subunits, along with β subunit variants and the γ2 subunit, and extra-
synaptic receptors containing the α4, α5 and α6 subunits, often along with the δ subunit. 
This observation implies that the mechanisms of subcellular targeting of GABAA recep-
tor subtypes are subunit specific, and can vary between CNS regions and developmen-
tal stages.  
Several approaches such as mutation, gene knockout and the inhibition of ex-
pression of GABAA receptor subunits by antisense oligodeoxynucleotides have been 
used to establish the role of various subunits and their receptor assemblies. With the 
use of transgenic mice was discovered that different α subtype subunits mediate dis-
tinct pharmacological actions of benzodiazepines (Rudolph et al., 2004): the α1 subunit 
mediates the sedative-hypnotic (Rudolph et al., 1999), the α2 subunit mediates the an-
xiolytic effect and in part that muscle relaxant (Löw et al., 2000). The use of a pseudo-
pregnant rat model and in vitro studies showed that α4 subunit seems to be important 
in mediating the GABAergic transmission in some physiological conditions, (Smith et 
al., 1998) or pharmacological (Follesa et al., 2000) associated with abrupt changes in 
the levels of neurosteroids. 
Furthermore recombinant receptors containing the α4 and α6 subunit bind with 
high affinity the benzodiazepine antagonist flumazenil, but very weakly classical ben-
zodiazepines such as diazepam (Wisden et al., 1991). It has been shown that a histi-
dine at the position α1H101 and homologous position in α2, α3 and α5 is crucial for ben-
zodiazepine action and α4 and α6 subunit isoforms carry an arginine in this position 
(Wieland et al. 1992, Dunn et al. 1999). 
The location of the picrotoxin binding site is controversial. Picrotoxin is reported 
to interact with residue Val256 (Xu, Covey and Akabas, 1995) and act as an open 
channel blocker or may inhibit channel function allosterically. (Ramakrishnan and Hess 
2005). In favour of the first hypothesis is the study which show that the mutation in the 
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homologous residue in Drosophila receptors confers cyclodiene and picrotoxin re-
sistance (ffrench-Constant et al., 1993). Moreover the crystal structure of the homo-
pentameric Caenorhabditis elegans glutamate-gated chloride channel (GluCL), which 
belong to the same cis receptor family like the GABAA receptor, show that picrotoxin 
directly occludes the pore near its cytosolic base of the lumen of the channel, at the 2’ 
Thr and -2’ Pro side chains (Hibbs and Gouaux, 2011). 
1.3.8 GABAA receptors in peripheral tissues 
Gamma-aminobutyric acid (GABA) and its receptors are found in a wide range 
of peripheral tissues, including parts of the peripheral nervous system, neuroendocrine 
cells including pancreatic (Taniguchi et al., 1979; Yang et al., 1994), pituitary (Racagni 
et al., 1983), and adrenal cells (Parramon et al., 1995). Subunits of GABA receptors 
have been demonstrated in non-neural tissues such as, lungs, gut, bladder, vascular, 
and uterine smooth muscle (Mizuta et al., 2008; Amenta et al., 1988; Ferguson and 
Marchant, 1995; Fujiwara and Muramatsu, 1975; Napoleone et al., 1991) in the im-
mune system (Bergeret et al., 1998; Tian et al., 1999; Alam et al., 2005; Dionisio et al., 
2013), in heart (Matsuyama, 1999), uterus (Hedblom, 1997; Neelands and Macdonald, 
1999), kidney (Sarang et al., 2001) and liver (Erlitzki et al., 2000; Sun et al., 2003). 
In contrast to the CNS, the role of GABA in the peripheral nervous system is not 
well defined. It has been known since 1950s that GABA exists in peripheral tissues of 
rodents and humans.  The general focus has been to localise and identify GABAergic 
functions pharmacologically. Selected tissue are discussed in the following. 
In airway smooth muscle cells, GABAA α4, α5, β3, and γ2 subunit proteins as-
semble in a functional GABAA receptor which seems to be responsible for the muscle 
relaxation, in fact the hyperpolarization induced by GABA results in a reduced intracel-
lular calcium, which will not be able to activate the Ca2+/calmodulin-dependent activa-
tion of myosin light chain kinase, resulting in reduced phosphorylation of myosin light 
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chain leading to a less muscle contraction (Mizuta et al., 2008). This study has a high 
impact for the therapy of diseases such as asthma and chronic obstructive lung dis-
ease. 
There is also evidence for the expression of inhibitory ligand-gated chloride 
channels in cells of the immune system. GABAA receptors are expressed in the human 
lymphocytes where mediate the communication between excitable cells on immune 
cells (Tian et al., 1999). Through these GABAA receptors, GABA can inhibit T cell re-
sponses to antigen both in vitro and in vivo inhibiting antigen-specific T cell prolifera-
tion. This function was mimicked by the GABAA receptor agonist muscimol, blocked by 
GABAA receptor antagonists and a GABAA receptor Cl− channel blocker (picrotoxin) 
and enhanced by pentobarbital (Tian et al., 1999). This finding is of pharmacological 
importance because modulation of GABAA receptors may provide new approaches to 
modulate T cell responses in inflammation and autoimmune disease.  
Moreover in patients seriously ill, on intensive care, the anaesthetic drugs 
propofol or thiopental are mostly used to induce sedation (Fraser and Riker, 2007). The 
use of this anaesthetic drugs in intensive care patients seem to increase the probability 
to develop serious infections, where 50% of patients with severe sepsis usually die 
(Nadal et al., 1995; Stover et al., 1998). According to a recent study, the increase in the 
risk of infection after the administration of the anaesthetic drug is due to their direct 
action on the GABAA receptors expressed in the monocytes, which inhibit the mono-
cytes physiological function. The activation of GABAA receptors in the monocytes is 
inhibited by picrotoxin, but is not enhanced by the positive modulator diazepam. The 
expression of α4, β2, γ1 and δ GABAA receptor subunits was detected in the monocytes. 
These receptors are insensitive to benzodiazepines, thus it is suggested from the au-
thors that benzodiazepine could be consider as an alternative drug to propofol and thi-
opental in patients developing severe sepsis (Wheeler et al., 2011). 
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The concentrations of GABA in the peripheral tissues are generally low, about 
1% of that in brain, with the exception of the female genital tract (Del Rio and Caballe-
ro, 1980) and pancreatic islets (Michalik and Ereciuska, 1992). In pancreatic islets, the 
GABA concentration is comparable to that of the CNS (Garry et al., 1986) and it is now 
clear that the activation of GABA receptors in islet β-cells increases insulin release 
(Bansan et al., 2011) exerts protective and regenerative effects on islet β-cells and 
reduces apoptosis in cultured islets (Dong et al., 2006).  
The role of the GABAA receptor in liver is described in more detail in chapter 
four of the thesis. 
1.4 Aims  
GABAA receptors bind and are inhibited by epileptogenic agents such as picro-
toxin, and cyclodiene insecticides such as dieldrin. The interaction site for picrotoxin is 
controversial. It may bind in the channel lumen and act as an open channel blocker or 
bind in a different binding sites and act allosterically. The aim of this project was to de-
scribe a novel inhibitor of rat GABAA receptors, the pentacyanocyclopentdienyl anion 
(PCCP-), an aromatic monovalent anion with five-fold symmetry. GABAA receptors 
show near five-fold symmetry that is most pronounced in the second transmembrane 
domain M2 lining the Cl- ion channel. PCCP- inhibited currents elicited by GABA with 
comparable potency as picrotoxin. This inhibition showed all characteristics of an open 
channel blocker, characterized by an apparent desensitization of the current, an off-
current and sensitivity to the membrane potential. Other anion selective cys-loop recep-
tors were also inhibited by PCCP-, e.g. the Drosophila RDL GABAA receptors, carrying 
instecticide resistence mutations. The thesis aimed to identify amino acid residues in 
M2 involved in the recognition of PCCP-. We used the substitute-cysteine accessibility 
method where consecutive residues in putative channel-lining were mutated to cysteine 
one at the time. With electrophysiological experiments we investigated if PCCP- could 
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protect the interaction between a positive charged cysteine reactive compound 
MTSET+ with the engineered cysteine residues exposed in the channel. 
An additional short term project in collaboration with an other PhD student Si-
mon Middendorp of Prof. Sigel’s laboratory was to characterised a light-switchable 
modulator of GABAA receptors called azopropofol (AP2).  It was my responsabiity to 
investigate the switching kinetics of this compound in patch clamp experiments. 
Another aim of the thesis was to investigate the role of GABAA receptors in the 
liver. The idea was based on an article (Minuk et al., 2007) showing expression of the 
GABAA receptor in the liver. We aimed to investigate expression pattern, localization 
and function of the hepatocytes GABAA receptors in model cell lines and healthy and 
cancerous hepatocytes. Due to its nature as chloride channel, which in other tissues 
regulate proliferation, we aimed to test the potential involvement in proliferation and 
liver regeneration. 
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2 Results 
2.1 Manuscript 1: A pentasymmetric open channel blocker for 
Cys-loop receptor channels 
Valentina Carta*, Michael Pangerl*, Roland Baur, Roshan Puthenkalam, Margot Ernst, 
Dirk Trauner, Erwin Sigel 
 
* These authors contributed equally to this study 
 
Abstract 
γ-Aminobutyric acid type A receptors (GABAA receptors) are chloride ion chan-
nels composed of five subunits, mediating fast synaptic and tonic inhibition in 
the mammalian brain. These receptors show near five-fold symmetry that is most 
pronounced in the second trans-membrane domain M2 lining the Cl- ion channel. 
To take advantage of this inherent symmetry, we screened a variety of aromatic 
anions with matched symmetry and found an inhibitor, pentacyanocyclo-
pentdienyl anion (PCCP-) that exhibited all characteristics of an open channel 
blocker. Inhibition was strongly dependent on the membrane potential. Through 
mutagenesis and covalent modification, we identified the region α1V256-α1T261 
in the rat recombinant GABAA receptor to be important for PCCP- action. Intro-
duction of positive charges into M2 increased the affinity for PCCP- while PCCP- 
prevented the access of a positively charged molecule into M2. Interestingly, 
other anion selective cys-loop receptors were also inhibited by PCCP-, among 
them the Drosophila RDL GABAA receptor carrying an insecticide resistance mu-
tation, suggesting that PCCP- could serve as an insecticide. 
 
Keywords: GABA, GABAA receptor, channel block 
 
Introduction 
Symmetry pervades nature at all levels from nuclear physics to astronomy [1]. 
In biology, it enables complex functions to arise from a limited set of building blocks 
and associated genes. A case in point is protein assemblies, such as viral capsids or 
trans-
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for the encapsulation of maximum space with a minimum number of protein compo-
nents [2]. The latter are often multimeric, for instance tetrameric (voltage-gated potas-
sium channels), pentameric (cys-loop receptors) or hexameric (Orai channels), with a 
central pore formed by membrane-spanning subunits. Following the establishment of a 
basic multimeric assembly early in evolution, a higher level of functional sophistication 
is sometimes achieved through subsequent desymmetrization, for instance through 
concatenation or heteromultimerization of closely related, yet distinct, subunits. 
GABAA receptors are a particularly interesting class of pentameric ligand-gated 
ion channels. They are composed of five subunits surrounding a central chloride ion 
channel and represent the major inhibitory receptors in the mammalian central nervous 
system [3-6]. The most abundant receptor isoform in mammalian brain consists of α1, 
β2, and γ2 subunits [7]. Various approaches have been used to derive the subunit stoi-
chiometry for this receptor, which has been determined as 2α:2β:1γ with a subunit ar-
rangement γβαβα anti-clockwise as seen from the synaptic cleft [8-12]. The pharmaco-
logical properties depend on subunit composition [13] and arrangement [14]. The sub-
units of GABAA receptors share a high degree of homology with other subunits of the 
same receptors, as well as subunits of other Cys-loop receptors. All these receptors 
have a near five-fold symmetry. The degree of symmetry is especially high in the se-
cond trans-membrane domain M2 that lines the ion channel (Figure 12A).  
GABAA receptors have a rich pharmacology and are targeted by numerous 
agents such as muscimol, picrotoxin, benzodiazepines and insecticides [15]. None of 
these ligands, however, takes advantage of the five-fold (or near five-fold) symmetry of 
the receptors and the availability of multiple, i.e. up to five, related contact sites. En-
couraged by recent work on polyvalent ligands [16], we hypothesized that small sym-
metric or nearly pentasymmetric anions would serve as symmetry-adapted blockers of 
the anion-selective GABAA receptors. 
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Figure 12. Aligned sequences of the amino acid residues in the subunits α1β2γ2 
of the rat GABAA receptor. A, Alignment of 2α, 2β and 1γ subunit contributing to the 
formation of a GABAA pentamer. The residues in the α1 subunit of the GABAA mutated 
to Cys are shown in boldface letters. B, α-Helical wheel representation of the rat α1 M2 
membrane-spanning domain showing the mutated residues in boldface letters. 
 
Such molecules would have multiple similar interactions with the protein, which 
would result in a sharp increase of overall binding affinity (avidity) due to the polyvalen-
cy effect [17]. To test this hypothesis, we synthesized a range of perfectly or nearly 
five-fold symmetric anions (Figure 13A) and investigated them in electrophysiological 
experiments. Among these, we identified the pentacyanocyclopentdienyl anion (PCCP-) 
as an inhibitor of GABAA receptors. Here we describe that PCCP- has all the hallmarks 
of an open channel blocker, discuss its binding site, and evaluate its interactions with 
other pentameric ligand-gated on channels. 
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Materials and Methods 
Compounds 1 (Na+PCCP-) and 2 were synthesized using established literature proto-
cols. Compounds 3 and 4 were synthesized from 2 by treatment with ammonia and 
hydrazine, respectively. Details of these syntheses will be published elsewhere. 
Crystallographic data (excluding structure factors) for Na+PCCP- (acetone solvate) 
have been deposited with the Cambridge Crystallographic Data Centre as publication 
no. CCDC-946841. Copies of the data can be obtained free of charge on application to 
CCDC, 12 Union Road, Cambridge.  
MTSET+ was obtained from Toronto Research Chemicals Inc. All the other chemicals 
were purchased from Sigma-Aldrich.  
The recombinant rat mutant subunits α1A253C, α1V256C, α1T260C, α1T261C, 
α1L263C, α1T264C, α1T267C putatively facing the channel lumen (Fig. 1A,B) were 
prepared using the QuikChange mutagenesis kit (Stratagene).  
Capped cRNAs were synthesized from the linearized plasmids. A poly-A tail of 
about 400 residues was added to each transcript using yeast poly-A polymerase. The 
concentration of the cRNA was quantified on a formaldehyde gel using Radiant Red 
stain for visualization of the RNA. Known concentrations of RNA ladder were loaded as 
standard on the same gel. cRNAs were precipitated in ethanol/isoamylalcohol 19:1, the 
dried pellet dissolved in water and stored at -80°C. Xenopus oocytes were prepared, 
injected and defollicated as described previously [18] (Research approved by the Kan-
tonstierarzt, Kantonaler Veterinärdienst Bern (Animal research permit BE98/12)). Brief-
ly, Xenopus laevis oocytes were injected with 50nL of the cRNA solution containing 
wild type or mutated α1, β2 and γ2 subunits at a concentration of 10 nM: 10 nM : 50 nM 
and then incubated in modified Barth’s solution at 18°C for at least 24 h before the 
measurements. Homomeric glycine receptors (β-subunit), heteromeric glycine recep-
tors (α and β-subunit) (cDNAs are a kind gift by B. Laube and H. Betz), the prokaryotic 
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ELIC (cDNA is a kind gift by R. Dutzler), the wild-type and the dieldrin resistant (RDL) 
mutant Drosophila GABAA receptor (wild type, bd splice variant and mutant A301S) 
(cDNAs are a kind gift by D. Sattelle) were also expressed.  
Currents were measured using a home-built two-electrode voltage clamp ampli-
fier in combination with a XY-recorder or digitized using a PowerLab 2/20 (AD Instru-
ments) using the computer program Chart. Tests with a model oocyte were performed 
to ensure linearity in the larger current range. The response was linear up to 15 µA. 
Electrophysiological experiments were performed by using the two-electrode voltage 
clamp method at a holding potential of -80 mV. The perfusion medium contained 90 
mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 5 mM Na-HEPES (pH 7.4) and 
was applied by a gravity flow of 6 ml/min. Wild type and and mutant receptors were 
characterized for their apparent affinity for γ-aminobutyric acid (GABA) for channel gat-
ing and for inhibition by PCCP- and picrotoxin. The GABA concentration response 
curve was determined by sequential application of increasing concentrations of GABA. 
Concentration-inhibition curves were performed at GABA (EC10) by sequential co-
application of GABA and increasing concentrations of PCCP- or picrotoxin. Inhibition 
was determined at the end of 1min co-application of GABA and PCCP- or picrotoxin. 
Concentration response curves were fitted with I(c)= Imax / (1+(c/EC50)^n, where I is the 
current potentiation, c is the concentration of GABA, Imax is the maximal current ampli-
tude, EC50 is the concentration of GABA at which a half-maximal current amplitude was 
observed and n is the Hill coefficient. Concentration inhibition curves were fitted with 
I(c) = Imax / (1+ (IC50/c)), where I is the control current amplitude, c is the concentration 
of PCCP- or picrotoxin, Imax is the control current amplitude elicited by GABA and IC50 is 
the concentration of PCCP- or picrotoxin at which half-maximal inhibition was observed.  
Drugs were applied as follows: 1 min GABA (EC10), 1 min GABA (EC10), 1 min GABA 
(EC10) + PCCP- (IC50), 1 min MTSET+ (5 mM) either in the presence or absence of 100 
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µM GABA, 1 min GABA (EC10), 1 min GABA (EC10), 1 min GABA (EC10) + PCCP- (con-
centration as before). Similar experiments were performed with picrotoxin.  
Due to the difficulty of washing out picrotoxin out from the oocytes two different 
oocytes were used to test the inhibition before and after the treatment with the cysteine 
reactive compound. Inhibition after treatment was divided by % inhibition before treat-
ment. To test the ability of PCCP- to protect the engineered cysteines from covalent 
modification by MTSET+, we used the same sequence of perfusion except that 
MTSET+ was co-applied with 1 mM PCCP-. Results were obtained on 3-4 single oo-
cytes for each receptor.The homology model is based on PDB entry 3RIF and was 
constructed with Modeller [19]. Ligand docking was performed with the GOLD software 
[20]. The binding site was defined to contain the 2´and 6’ residues, side chains α1T260, 
β2T256 and γ2T271 were kept flexible during docking. 
 
Results 
Synthesis and preliminary biological evaluation.  
Figure 13A shows the investigated symmetry-adapted anions. PCCP- as its sodium 
salt 1 and compound 2 were synthesized following established literature procedures 
[21-23]. Compounds 3 and 4 were prepared from 2 by treatment with ammonia and 
hydrazine, respectively. Details of these syntheses will be published elsewhere. Com-
pounds 1-4 were tested for inhibition of recombinant α1β2γ2 GABAA receptors. Among 
these, only 1 was found to be highly active and was further characterized and the x-ray 
structure determined (Figure 13B). 
Low concentrations of PCCP- inhibit currents mediated by α1β2γ2 GABAA recep-
tors.  
To evaluate PCCP- as an ion channel blocker, α1β2γ2 rat GABAA receptors were ex-
pressed in Xenopus oocytes. At concentrations of 0.3 - 10 µM PCCP- stimulated cur-
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rents elicited by low concentrations of GABA (EC1). This stimulation was highly variable 
between individual oocytes and was not mediated by the site for benzodiazepines as 1 
µM Ro15-1788 fails to affect the stimulation. As stimulation was only observed at low 
concentration of GABA, we are tempted to assume a different site of action of PCCP- 
for stimulation and inhibition. At higher concentrations (> 1 µM), PCCP- induced an 
open-channel block, characterized by an apparent desensitization of the current and an 
off-current. As expected, this block became more prominent with increasing agonist 
concentrations. Stimulation became less evident. Original current traces and averaged 
data are shown in Figure 14A,B.  
 
 
Figure 13. Symmetry-adapted anions, the chemical structure of PCCP- and the X-
ray structure of Na+PCCP-. A, Symmetry-adapted anions. B, X-ray structure of 
Na+PCCP- (as the acetone solvate). The network of coordinative interactions between 
the partially negatively charged nitrogen atoms of PCCP- and the Na+ cations is high-
lighted. The insert indicates the geometry of the molecule. 
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Figure 14. Effect of PCCP- on recombinant α1β2γ2 GABAA receptors. A, GABAA 
receptors were expressed in Xenopus oocytes. The electrical currents recorded by two-
electrode voltage clamp were activated with a concentration of GABA eliciting 1% of 
the maximal current amplitude (EC1) and inhibited with increasing concentrations of 
PCCP-. The lower bar indicates the time of GABA application, the upper bar the time of 
PCCP- application. The numbers indicate the concentration of PCCP- in µM. At concen-
trations > 1 µM, induces an open-channel block, characterized by an apparent desensi-
tization of the current and an off-current. B, Averaged concentration inhibition curve by 
PCCP-. Individual curves were fitted and standardized to the current elicited by GABA. 
Data are shown as mean ± SEM (n = 4). Open circle: peak current amplitudes at the 
beginning of the drug application. Filled squares: current amplitudes at the end of the 
drug application. Filled circles: current amplitudes at the end of the drug application 
corrected for the direct effect of PCCP- on membranes. C) and D) same experiment 
carried out at a concentration of GABA eliciting 10% of the maximal current amplitude 
(EC10). 
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Figure 14C,D shows a similar experiment carried out at a higher GABA con-
centration (EC10). At this GABA concentration, PCCP- only exhibited a channel block. 
Current amplitudes measured after 1 min application of GABA and PCCP- were fitted 
with an IC50 of 2.6 ± 0.8 µM (n = 4). In additional experiments PCCP- was pre-applied 
for 30 s before the combined application of PCCP- with GABA. Current traces looked 
the same as without pre-application, indicating that PCCP- did not interact with closed 
channels. 
PCCP- also inhibited α1β2γ2 and α1β2δ rat GABAA receptors, respectively, with an IC50 of 
12.5 ± 4.8 µM (n = 4) and 0.71 ± 0.28 µM (n = 4) (Figure 15 A).  It should be noted that 
the primary sequences of β1 and β2 differ substantially in the inner leaflet of M3.  
 
 
 
Figure 15. Concentration inhibition curves for rat and Drosophila GABAA recep-
tors. A, Concentration inhibition curve for α1β2γ2 and α1β2δ GABAA receptors. Increas-
ing concentrations of PCCP- were applied together with GABA EC10. Individual inhibi-
tion curves were standardized and subsequently averaged (Mean ± SD, n=4). Data are 
compared with those obtained from α1β2γ2 receptors. Inhibition of the wild type and mu-
tant RDL Drosophila GABAA receptor by PCCP- and Picrotoxin.  
Concentration inhibition curves of (B) PCCP- and, (C) picrotoxin were determined in 
wild type (circles) and mutant (squares) receptors. Currents were activated with a con-
centration of GABA eliciting 10% of the maximal current amplitude (EC10) and inhibited 
with increasing concentration of PCCP- or picrotoxin. Individual curves were standard-
ized to initial current amplitudes and subsequently averaged. Data are shown as mean 
± SD (n = 3). 
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Glycine homomeric and heteromeric receptors [24] were similarly inhibited, while ELIC 
[25] required about 100 µM PCCP- for half-maximal inhibition.  
Inhibition by PCCP- was strongly dependent on the membrane potential (Figure 
16). IC50 was 16.2 ± 1.3 µM (n = 3) at -120 mV, 6.3 ± 1.3 µM (n = 3) at -80 mV and 1.8 
± 0.8 µM (n = 3) at -40 mV. It should be noted that the IC50 at -80 mV was for unknown 
reasons somewhat higher than determined in the experiments before. From these val-
ues one can estimate the fraction of the voltage field experienced by the blocking parti-
cle at its blocking site from the equation derived by Woodhull [26] where δ is the frac-
tion of the voltage field sensed by the blocker from the outside of the membrane.  
 
 
Figure 16. Effect of the membrane potential on inhibition by PCCP-. A, GABAA 
receptors were activated with a concentration of GABA eliciting 10 % of the maximal 
current amplitude (EC10) and inhibited with increasing concentrations of PCCP-. Aver-
aged concentration inhibition curves by PCCP- are shown for different membrane po-
tentials. Individual curves were fitted and standardized to the current elicited by GABA. 
Data are shown as mean ± SD (n = 3) 
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δ was estimated to be ~ 0.7 the distance of the voltage field from the extracellular side. 
In additional experiments it was tested of inhibition by PCCP- was of competi-
tive or non-competitive nature. GABA concentration response curves were carried out 
in the absence of PCCP- or the presence of 2 µM or 10 µM PCCP-. Analysis was com-
plicated by the fact that currents were determined after 1 min application of GABA, 
when a substantial proportion of the channels had been desensitized. Nevertheless 
data showed rather a leftward shift of the GABA concentration response curve with 
increasing concentrations of PCCP-, a phenomenon excluding competitive inhibition. 
High concentrations of PCCP- interact with the lipid bilayer.  
At concentrations ≥ 10 µM, PCCP- induced a current in non-injected oocytes. Perfusion 
of 10, 30 or 100 µM PCCP- at a holding potential of -80 mV resulted in small outward 
currents (Figure 17B). Upon a voltage jump from -80 to -30 mV, µA sized currents of 
more than 30 ms duration were observed in the presence of 100 µM PCCP- (Figure 
17A).  Thus it appears that PCCP- is able to insert into the bilayer and diffuse through 
the bilayer, reflecting its lack of dipole moment and relative lipophilicity (clogP = -0.48). 
It should be noted that the concentrations of PCCP- required to induce currents in non-
injected oocytes are much larger than the concentrations required to inhibit GABAA 
receptor channels.  
PCCP- inhibits currents mediated by wild type and mutant RDL Drosophila 
GABAA receptor to a similar extent.  
Mutation A302S in RDL Drosophila GABAA receptors has been reported to confer a 
certain degree of resistance to inhibition by picrotoxin [27,28]. In our hands, a 7-fold 
reduction in sensitivity to picrotoxin upon the mutation was observed. Interestingly, 
PCCP- showed a much smaller (about 2-fold) difference in the IC50 between wild type 
and mutant receptors (Figure 15B,C). 
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Pharmacological properties of mutant receptors.  
To identify important residues for the interaction with PCCP-, we mutated, one at a 
time, seven residues in M2 of α1 to cysteine residues. (Figure 12A,B). Mutated α1 sub-
units were co-expressed with wild type β2 and γ2 subunits in Xenopus oocytes. The 
sensitivity to GABA was tested for the different mutants. Expression of α1L263Cβ2γ2 
resulted in a spontaneously open channel. While α1A253Cβ2γ2, α1T260Cβ2γ2, 
α1T267Cβ2γ2 showed an EC50 similar to wild type receptors, the mutant α1V256Cβ2γ2 
showed an about 10-fold increase and the mutants α1T261Cβ2γ2 and α1T264Cβ2γ2 
showed an about 4 fold decrease in the EC50 for GABA (Figure 18A; Table 1).  The 
sensitivity to inhibition by PCCP- of GABA-activated currents was also determined for 
wild type and mutant receptors. A GABA concentration eliciting 10% of the maximal 
Figure 17. High con-
centration of PCCP- 
induce a current in 
non-injected Xenopus 
oocytes. A, Voltage 
jump of 25 ms  duration 
from -80 mV to -30 mV. 
A µA sized transient 
current flows with each 
voltage step. B, A small 
transient outward cur-
rent is induced after ap-
plications of 10, 30, and 
100 µM PCCP- of 30 s 
duration to an oocyte 
held at a membrane 
potential of -80 mV 
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current in the corresponding receptor was used in these experiments. The mutant re-
ceptors α1V256Cβ2γ2 and α1T261Cβ2γ2 displayed each an about 20-30 fold reduced 
sensitivity to PCCP- compared with wild type receptors (Figure 18B; Table 1). The 
sensitivity of GABA-activated currents to picrotoxin was also determined using the 
same conditions as for PCCP- (Fig. 18C; Table 1). Little effect of the studied mutations 
was observed on the IC50 for picrotoxin. 
 
 
Figure 18. Pharmacological 
properties of wild type and cys-
teine mutant GABAA receptors. 
A, GABA concentration response 
curves from wild type and mutant 
rat GABAA receptor. B, PCCP- and 
C, picrotoxin concentration inhibi-
tion curves. Individual curves were 
fitted and standardized. Data are 
shown as mean ± SD (n=3 to 4) 
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Table 1. Pharmacological evaluation of the expressed recombinant receptors. EC50 for 
GABA, IC50 for PCCP-, and IC50 for picrotoxin are given for wild type and mutant recep-
tors. 
 
Receptor GABA 
EC50 (µM) 
mean ± SD 
 
 
n 
PCCP- 
IC50 (µM) 
mean ± SD 
 
 
n 
Picrotoxin 
IC50 (µM) 
mean ± SD 
 
 
n 
α1β2γ2 31.3 ± 6.5 3 2.58 ± 0.75 3 2.02 ± 0.89 6 
α1A253Cβ2γ2 30.6 ± 6.4 3 2.63 ± 0.31 3 1.79 ± 0.15 3 
α1V256Cβ2γ2 2.91 ± 7.4 4 62.2 ± 22.4 4 0.74 ± 0.36 4 
α1T260Cβ2γ2 44.1 ± 6.4 4 0.85 ± 0.46 4 1.31 ± 0.41 3 
α1T261Cβ2γ2 111  ± 1 3 46.4 ± 7.25 3 1.31 ± 0.71 3 
α1L263Cβ2γ2 open ch. 3 4.47 ± 1.36 3 1.10 ± 0.21 3 
α1T264Cβ2γ2 126  ± 24 4 3.15 ± 0.48 3 1.03 ± 0.35 3 
α1T267Cβ2γ2 32.2 ± 11.9 3 0.77 ± 0.11 3 0.83 ± 0.48 3 
 
 
The effect of MTSET+ on the cysteine-substitution mutants and the binding site 
of PCCP-.  
A cysteine scan was chosen as it allows covalent reaction with a cysteine reactive 
compound to potentially increase the effect seen with the mutation alone, to test ac-
cessibility of the residue and to investigate protection from the covalent reaction by a 
compound. In preliminary experiments pCMBS-, MTSEA+ and MTSET+ were tested. 
Only treatment with MTSET+ left wild type GABAA receptors unaffected (Figure 19A). 
Therefore MTSET+ was chosen for further experimentation. Current traces for wild type 
receptor and α1V256Cβ2γ2 and α1T260Cβ2γ2 mutant receptors are shown in Figure 
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19B,C and Figure 20A,B, illustrating typical experiments where we chose an inhibitor 
concentration such as to inhibit about 50% of the late current response elicited by 
GABA (EC10) in the corresponding receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. PCCP- prevents the increase in PCCP- sensitivity of α1V256β2γ2 medi-
ated by MTSET+ + GABA. GABA (EC10) was applied repetitively until a stable current 
response was observed followed by inhibition of the channel by PCCP-. Subsequently 
5 mM MTSET was applied in the presence of GABA. After MTSET+ treatment GABA 
was applied twice followed by a combined application of GABA and the same concen-
tration of PCCP- used before. A, Wild type receptors were not affected by this treat-
ment. B, The treatment leads to an enhanced inhibition in α1V256Cβ2γ2. C, 5 mM 
MTSET+ was applied to α1V256C mutant receptor in presence of GABA and 1 mM 
PCCP-. PCCP- prevented enhanced inhibition and therefore covalent reaction. These 
experiments were repeated independently three times using different oocytes. 
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MTSET+ + GABA treatment applied for 1 min to the wild type receptor had no effect on 
the affinity for PCCP- (Figure 19A). MTSET+ + GABA treatment in α1V256Cβ2γ2 led to 
an increase in PCCP- inhibition (Figure 19B). This effect could be prevented when 1 
mM of PCCP- was present during the treatment (Figure 19C). The Figure 20A shows 
that MTSET+ + GABA treatment leads to a spontaneously open channel in the 
α1T260Cβ2γ2 mutant, characterized by a shift on the base line of the current. We ap-
plied increasing concentrations of PCCP- to investigate if PCCP- was able to block the 
channel again. 
 
 
Figure 20  PCCP- prevents the increase in PCCP- sensitivity of α1T260β2γ2 mediated 
by MTSET+ + GABA. GABA (EC10) was applied repetitively until a stable current re-
sponse was observed followed by inhibition of the channel by PCCP-. Subsequently 5 
mM MTSET+ was applied in the presence of GABA. After MTSET+ treatment GABA 
was applied twice followed by a combined application of GABA and the same concen-
tration of PCCP- used before. A, The treatment leads to a spontaneously open channel 
and an enhanced inhibition in α1T260Cβ2γ2. B, 5 mM MTSET+ was applied to α1T260C 
mutant receptor in presence of GABA and 1mM PCCP-. PCCP- prevents the open 
channel formation. These experiments were repeated independently three times using 
different oocytes. 
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The IC50 value after the treatment was 9 ± 0.3 nM (mean ± SD, n = 3) as compared to 
the IC50 of 0.85 ± 0.46 µM (n = 3) before the treatment. This indicates a strongly en-
hanced affinity for PCCP-. Moreover, as the maximally inhibited current level almost 
reached the original base line we conclude that PCCP- was able to close the channel 
again. Figure 20B documents that presence of 1 mM PCCP- during MTSET+ + GABA 
treatment prevents the open channel formation and the affinity for PCCP- was the 
same before and after the treatment.  
Figure 21 summarizes our observations in wild type and mutant receptors. The bars 
indicate the ratio of the percentage of inhibition by PCCP- (or picrotoxin) observed after 
application divided by that before the application of MTSET+ (black bars). The diagrams 
on the left show this ratio for PCCP- (Figure 21A) and picrotoxin (Figure 21C) after 
application of MTSET+ without GABA and the diagrams on the right show the above 
ratio for PCCP- (Figure 21B) and picrotoxin (Figure 21D) after application of MTSET+ 
in the presence of GABA. A value of 1 indicates that the IC50 before and after MTSET+ 
treatment were the same. An increase in the value indicates a decrease in the IC50 of 
an inhibitor (increase in apparent affinity) and a decrease below 1 the opposite. 
MTSET+ treatment in the absence of GABA caused generally little change in the ap-
parent affinity of both channel inhibitors (Figure 21A,C). An exception is the mutant 
α1L263Cβ2γ2 with a significant increase in the ratio for PCCP- (p < 0.01) and a signifi-
cant decrease in the ratio for picrotoxin (p < 0.001). This mutation leads to an open 
channel, to the lumen of which MTSET+ obviously has access in the absence of GABA. 
For those mutations already slightly affected by the MTSET+ treatment alone, the effect 
on the inhibition by PCCP- increased when the MTSET+ treatment was carried out in 
presence of 100 µM GABA. The application of MTSET+ + GABA caused a significant 
increase in the % inhibition by PCCP- in α1V256Cβ2γ2, α1T260Cβ2γ2, α1T263Cβ2γ2, 
α1T264Cβ2γ2 and α1T267Cβ2γ2 (each p < 0.01) mutants (Figure 20B). 
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Figure 21.  Effect of MTSET+ on the PCCP- and picrotoxin inhibition of wild type 
and mutants GABAA receptors. Currents were elicited with GABA EC10. The concen-
tration of PCCP- or picrotoxin was chosen such as to inhibit about 50% of the late cur-
rent response in the corresponding receptor. Subsequently oocytes were treated with 
the cysteine-reactive reagent MTSET+ and inhibition by the same concentration of 
PCCP- or picrotoxin was determined. The ratio of the inhibition after treatment divided 
by inhibition before treatment is shown as a bar. A, C, MTSET+ was applied in the ab-
sence of GABA. B, D, MTSET+ was applied in the presence of 100 µM GABA. The 
circle symbol on top of the bar for the T260C and T264C mutations indicates formation 
of an open channel after MTSET+ treatment when applied in the presence of GABA. 
The white bars show results of experiments where the MTSET+ + GABA treatment was 
performed in the presence of 1 mM PCCP- or 1 mM picrotoxin, in order to see if the 
covalent reaction could be prevented by the channel blockers. The asterisks sign (*) 
indicates that 1 mM picrotoxin was not able to suppress formation of open channels. 
Mean ± SD is shown.  The number of oocytes for each experimental condition is either 
three or six. 
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Discussion 
Based on symmetry considerations, we have identified an aromatic monovalent 
anion with five-fold symmetry, PCCP-, as inhibitor of rat GABAA receptors. The expo-
sure to increasing concentrations of PCCP- causes inhibition in the GABA-evoked cur-
rent typical for an open channel blocker. All the pentameric receptors belonging to the 
Cys-loop family share a near five-fold symmetry which is most pronounced in the se-
cond transmembrane domain M2. PCCP- can also inhibit glycine homomeric and het-
eromeric receptors with similar affinity to the GABAA receptor and with smaller affinity 
ELIC. Interestingly, PCCP- also inhibits Drosophila wild type and mutant RDL channels 
carrying the dieldrin resistance mutation [27,28] suggesting a possible use of PCCP- as 
insecticide. High concentrations of PCCP- induced currents by themselves. We ascribe 
this phenomenon to distribution of PCCP- into the lipid bilayer and permeation through 
the bilayer. PCCP- lacks a dipole moment and is therefore comparatively lipophilic with 
a clogP of -0.48. However, we can not exclude an action of PCCP- on channels endog-
enous to the oocyte. 
 We studied the molecular site of interaction of PCCP- on α1β2γ2 GABAA recep-
tors. A series of cysteine mutations were introduced in M2 into amino acid residues of 
the α1 subunit. We selected residues that have been proposed to line the ion channel 
α1A253, α1V256, α1T260, α1T261, α1L263, α1T267 [29,30] (Figure 12A,B). The mutant 
receptors α1L263Cβ2γ2 form an open channel that could not be activated by GABA. 
This leucine residue is conserved in all known subunits of acetylcholine, glycine and 
GABAA receptors. It has been postulated that this residue plays a role in the gating 
mechanism of the channel, where the closure is achieved when the large hydrophobic 
leucine residues move into the channel inhibiting ion flux (for review see [31]). Most of 
the mutations studied here had little effect on the apparent affinity to GABA. Mutations 
in residues α1V256 and α1T261 each caused an approximately 30-20 fold decrease in 
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the apparent affinity of PCCP- to inhibit currents induced by GABA. This may suggest 
that PCCP- directly interacts with these residues, but it cannot be excluded here that 
these two residues allosterically affect the PCCP- binding site. The mutations did not 
affect the apparent affinity for picrotoxin to inhibit current elicited by GABA. 
It was of interest to test accessibility of the introduced cysteines to a cysteine 
reactive reagent. MTSET+ was chosen as it had a negligible effect on wild type recep-
tors. It should be noted that a receptor pentamer has two α1 subunits and that covalent 
reaction of a mutated receptor with MTSET+ introduces two positive charges. Evidence 
was obtained that MTSET+ has better access to the channel lumen in the presence of 
the channel agonist GABA and can penetrate as far as α1V256. Similar observations 
have been made by Xu et al. [32] using a different cysteine reactive reagent.  
Interestingly, covalent reaction of MTSET+ with α1V256Cβ2γ2, α1T260Cβ2γ2, 
α1L263Cβ2γ2, α1T264Cβ2γ2 and α1T267Cβ2γ2, led to an increase in the apparent affinity 
for PCCP- for channel inhibition. The fact that introduction of a relatively bulky moiety 
leads to an increase in affinity is probably due introduction of positive charges that fa-
vorably interact with the negatively charged PCCP-. Covalent reaction of MTSET+ with 
α1V256Cβ2γ2, α1T260Cβ2γ2 and α1T267Cβ2γ2 was prevented in the presence of PCCP-. 
The simplest interpretation of our observations including the direct effect of the muta-
tions α1V256C and α1T261C on the affinity of PCCP- is that PCCP- can penetrate al-
most down to the level of α1V256C. Binding of PCCP- then prevents MTSET+ access 
by channel constriction (Figure 22). However, we cannot exclude that PCCP- has a 
second binding site at the level of α1T267 that is not sensitive to the mutation of this 
residue to cysteine.  
Hydrophobic anions have previously been described to inhibit GABAA receptors 
in a voltage independent fashion [33] reportedly in the absence of a conventional ligand 
binding site. Similar to the observations made here the mutation of residue α1V256 
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located in M2 affected inhibition. We can not fully exclude the possibility of an action of 
PCCP- outside the channel, but following observations are in line with the existence of 
a binding site for PCCP- within the channel: a) off currents upon removal of PCCP-, b) 
site of action in the inner leaflet of the membrane (coinciding with the location of 
α1V256/α1T260/α1T261, c) increase in the affinity for PCCP- after introduction of posi-
tive charges in the form of MTSEA+ into M2 and d) prevention by PCCP- of the reaction 
of MTSEA+ in different positions. 
PCCP- is a rigid symmetric molecule with a diameter of approximately 10Å that 
can engage in interactions with metals and form hydrogen bonds with its five peripheral 
nitrogen atoms. These bonds can extend along the C,N-axis or at a slightly bent angle 
(Figure 12B).  
 
 
 
Figure 22. Hypothetical model for the mechanism of action of PCCP-. Mutation of 
residues α1V256 and α1T261 to cysteine alters strongly the apparent affinity for chan-
nel inhibition by PCCP-. The fact that MTSET+ can only react with cysteines introduced 
in M2 in the presence of GABA indicates that GABA widens the pore. For the mutations 
α1V256C and α1T260C the affinity for PCCP- is strongly increased after MTSET+ treat-
ment. MTSET+ reaction is prevented by PCCP-. This together implies these residues in 
PCCP- binding. Introduction of two positive charges by reaction with MTSET+ further up 
in the channel leads to additional binding sites for PCCP-. 
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Figure 23. Molecular model of the interaction of PCCP- with GABAA receptors. A, 
The side view of the PCCP- docking pose from the perspective of the γ2 subunit. The 
ligand and the mutated residues of the α1 subunit, which have an impact on the affinity 
of the ligand, are shown in space filling representation. The 2’ valines of the α1 subunit 
are rendered grey; the 6’ threonines of the α1 subunit in green. The GABAA receptor is 
displayed in ribbon representation with α1 subunits shown in yellow, β2 subunits in red, 
γ2 subunit in blue. The complete transmembrane domain (TMD) is shown only of the α1 
and the β2 subunits in the back. Of the subunits in front, only a segment of the trans-
membrane domain 2 (TMD2) is depicted. The TMD2 of the γ2 subunit is only partly dis-
played to provide a “window” through which the ligand is seen. B, Top view of the pose 
showing the symmetric molecular interactions between ligand and receptor. PCCP- 
(space filling) forms H-bonds (blue dashed lines) to the –OH groups of the 6’ threo-
nines (stick representation) of each of the five subunits. 
 
We think that the most likely interpretation of our findings is that PCCP- blocks the re-
ceptor by plugging the pore at the level of α1V256C, α1T260 and α1T261, adopting a 
position parallel to the lipid bilayer. Figure 23A,B depicts a molecular model of the 
binding site of PCCP-. The ligand is in a planar position between the highly conserved 
6’ level threonines (α1T260) forming H-bonds with the hydroxy groups, and the variable 
2’ level of α1V256 and the homologous β2A251 and γ2T267. These protein-ligand con-
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tacts are consistent with the observed affinity differences for different pentamers, as 
the shape complementarity and surface properties of the 2’ level will be unique for each 
homo- or hetero-pentameric receptor. The relatively slow rate of block could be due to 
the strong tendency of PCCP- to form H-bridges. It may be hypothesized that on the 
way down the channel lumen it interacts several times with the receptor. 
It is interesting to compare the binding site for PCCP- to that of picrotoxin, a 
well-known open channel blocker. Considerably controversy exists if picrotoxin oc-
cludes the channel directly or whether it allosterically affects the channel (reviewed in 
[34] and references therein). Possibly the best evidence for channel occupancy comes 
from crystallization experiments. The crystal structure of the homo-pentameric Caeno-
rhabditis elegans glutamate-gated chloride channel α (GluCl) shows that picrotoxin (9 
Å diameter) directly occludes the pore near its cytosolic base at the 2’ Thr and -2’ Pro 
side chains [35]. In this position, the channel diameter in static condition of the crystal 
is 4.6 Å. These residues are homologous to P252 and V256 in the M2 of the α1 GABAA 
receptor subunit. Thus, it appears that PCCP- and picrotoxin occupy sites in the lumen 
of the channel toward the intracellular side of the transmembrane domain that are 
shifted by one turn of the α-helix. 
Pentasymmetric protein assemblies are not confined to Cys-loop receptors but 
frequently occur elsewhere in Nature, for instance in mechanosensitive ion channels, 
such as MscL, or bacterial toxins, such as Shiga toxin B. Indeed, symmetry-adapted 
inhibitors for the latter have been developed that show extremely high avidity (picomo-
lar) due to their polyvalency [36]. More recently, polycationic blockers of voltage gated 
potassium channels based on a four-fold symmetric calixarenes [36] and a blocker of 
the heptameric Anthrax PA channel based on seven-fold symmetric β-cyclodextrin [37] 
have been introduced. This underscores that symmetry considerations hold considera-
ble promise for the development of new pharmacophores. Given the prevalence of 
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symmetric protein assemblies in Nature, it seems likely that many symmetry adapted 
agonists, antagonists and blockers will emerge in future years.  
In conclusion, we have identified a new potent blocker of GABAA receptors 
through rational design rather than a massive screening effort. Our work demonstrates 
that symmetry considerations can contribute to the pharmacology of Cys-loop recep-
tors. The application of other five-fold-symmetric molecular platforms including some 
shown in Figure 12 to the development of high-affinity ligands for GABAA receptors as 
well as other five-fold symmetric ion channels such as mechanosensitive channels is 
under active investigation and will be reported in due course. 
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2.2 Manuscript 2: Azo-propofols: photochromic potentiators 
of GABAA receptors. 
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Abstract 
Shine and rise! GABAA receptors are ligand-gated chloride ion channels that re-
spond to γ-aminobutyric acid (GABA), which is the major inhibitory neurotrans-
mitter of the mammalian central nervous system. Azobenzene derivatives of 
propofol, such as compound 1, increase GABA-induced currents in the dark 
form and lose this property upon light exposure and thus function as photo-
chromic potentiators. Compound 1 can be employed as a light-dependent gen-
eral anesthetic in translucent tadpoles. 
 
Keywords: azo compounds, GABA receptors, ion channels, photochromism, photo-
pharmacology. 
 
Introduction 
GABAA receptors are pentameric ligand-gated ion channels that are activated 
by the major inhibitory neurotransmitter in the mammalian brain, γ-aminobutyric acid 
(GABA).[1] Binding of GABA results in the opening of a chloride ion selective pore, thus 
hyperpolarizing the postsynaptic neuron and decreasing the likelihood of actionpotetial 
firing. As such, GABAA receptors are a prominent target for anesthetic, hypnotic, and 
anticonvulsant drugs (Scheme 1).[2, 3] While agonists, antagonists, and blockers of 
GABAA receptors, such as muscimol, gabazine, or picrotoxinin, respectively, have 
proven to be valuable research tools, their impact on human medicine has been lim-
ited. Drugs that target these receptors are dominated by allosteric modulators that po-
tentiate, that is, increase, chloride currents elicited by the neurotransmitter. Well-
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established potentiators include benzodiazepines (e.g. clonazepam), barbiturates (e.g. 
phenobarbital), the imidazopyridine zolpidem, and the simple phenol propofol.[2] These 
drugs bind to distinct allosteric sites on GABAA receptors, thereby increasing the mean 
open time or the opening frequency of the channel. However, the analysis of their exact 
binding sites at a molecular level has been complicated by a lack of detailed structural 
data. 
 
 
Scheme 1. Agonists (GABA, muscimol), antagonists (gabazine), blockers (picro-
toxinin), or potentiators (clonazepam, phenobarbital, zolpidem, propofol) of 
GABAA receptors. 
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After its discovery in 1980, propofol has become the most widely used intrave-
nous general anesthetic.[4] Although its mode of action has not been fully elucidated, it 
is commonly accepted that the anesthesia induced by this unusually lipophilic drug 
mostly results from potentiation of GABA-induced currents, as well as a direct activa-
tion of the chloride ion channel at high concentrations. Propofol has a rapid onset and 
offset of action and shows only minimal accumulation upon prolonged use. The intra-
venous administration of propofol is also associated with reduced postoperative nau-
sea and vomiting.[5]  
While GABAA receptors respond to a variety of ligands, they are normally not 
sensitive toward light. It would be fascinating to confer light sensitivity to these ion-
channels, since light is unsurpassed in terms of the temporal and spatial precision it 
provides. This light sensitivity could be indirectly achieved by using ligands that act on 
the receptors but can be optically switched between an active and an inactive form. 
Photochromic ligands of GABAA receptors could be agonists, antagonists, or allosteric 
modulators. In principle, these ligands could be covalently attached as photoswitched 
tethered ligands (PTLs) or act as soluble photochromic ligands (PCLs).[6] Indeed, both 
approaches have been used to convert neuronal[7] and neuromuscular[8] nicotinic ace-
tylcholine receptors, another type of pentameric ligand-gated ion channels, as well as 
ionotropic glutamate receptors[9] into artificial photoreceptors. Tethered and soluble 
photochromic blockers of K+, Na+, and Ca2+ ion channels have been described as well 
and have been used to control heartbeat,[10] pain sensation[11] and visual responses[12] 
in different animals with light. We now report photochromic potentiators of GABA cur-
rents that change the strength of GABA-induced currents in a light-dependent fashion. 
Our program was prompted by a recent report on a photoaffinity probe based 
on propofol, p- 4-aziC5-propofol that underscored that a relatively large substituent in 
the para-position of the phenol would be tolerated and that the propofol pharmacophor 
would be compatible with photochemistry (Scheme 2a).[13] 
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Scheme 2. a) p-4-aziC5-propofol, a photoreactive derivative of propofol, and AP1-16, 
photoswitchable derivatives of propofol. b) Synthesis of AP1 and AP2, which is shown 
in its trans and cis configuration. c) X-ray structure of trans-AP2; C green, O red, H 
white, N blue. 
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Accordingly, we designed a series of azobenzene derivatives of propofol; in 
these derivatives an aryldiazene unit is directly coupled to the pharmacophor. These 
molecules, termed azo-propofols 1–16 (AP1–16) are shown in Scheme 2a.  
In addition to this, the substitution of the azobezene core with electron-donating 
substituents greatly decreases the thermal stability of the cis isomer. Therefore, AP2 
quickly reverts to its trans form once the light is switched off. Since the absorption 
spectra of the cis and trans isomers are very similar (see the Supporting Information), 
this process cannot be accelerated by irradiation with a different wavelength. Other 
APs studied have less favorable photophysical properties, show decreased potency 
(e.g. AP3, AP9, AP10), no activity at all (e.g. AP4),[14c] or unfavorable solubility and dis-
tribution (e.g. AP6). 
 
Results 
The effect of AP2 on Cl- currents was investigated with electrophysiology using 
α1β2γ2 GABAA receptors expressed in Xenopus oocytes (Figure 24).[16] This receptor 
subtype represents the most prevalent form in the human brain.[17] First, the heterolo-
gously expressed GABAA receptors were exposed to GABA at a concentration eliciting 
0.3% of the maximal current amplitude in combination with increasing concentrations of 
propofol or AP2 in the dark to compare the relative effect of the compounds. From the 
resulting dose– response curves, we extracted an EC50 value of (17.1 ± 2.9) µM for 
propofol and of (6.1 ± 0.4) µM for AP2 (mean ± standard error of the mean (SEM), n = 
4 ; Figure 1a). Thus, AP2 in its dark-adapted trans form has a significantly higher affini-
ty than propofol itself, albeit its efficacy is reduced by about two fold when compared 
with its parent compound.  
Having established that AP2, in its dark-adapted form, has an effect on GABAA 
receptors, we investigated the light dependency of the current potentiation. UV/Vis light 
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from an Ultrafire 1Watt UV LED pocket lamp (YonC Trading, Zürich; emission wave-
length 390–450 nm) had no effect on the GABA response or the combined 
GABA/propofol response (data not shown).  
Figure 24b illustrates the effect of UV/Vis light on currents elicited by the com-
bined application of GABA and AP2. Stimulation of GABA currents by AP2 (1.5 µM) 
was (159 ± 25)% (mean ± SEM, n = 6). Exposure to light decreased the residual stimu-
lation to (18 ± 3)% (mean ± SEM, n=6). Similar observations were made using a UV 
high power LED pocket lamp, 5 Watt (Uveco GmbH, Bruckmühl, Germany), emission 
wavelength 355-380 nm equipped with a CHROMA bandpass filter D365/ 10x, to limit 
light emission to 360-370 nm.  
The possibility to use these different light sources reflects the broad absorption 
spectrum of AP2. Owing to redistribution of the hydrophobic compound AP2 into egg 
yolk, the rate of photoswitching could not be determined in Xenopus oocytes. For this 
purpose, we expressed α1β2γ2 GABAA receptors in HEK cells and performed experi-
ments using the whole-cell patch- clamp technique. GABA was co-applied with AP2.  
Subsequently, the perfusion was stopped to prevent arrival of new trans-AP2 
during the measurement, and the cells were exposed to the light. The current ampli-
tude decreased rapidly and increased again upon turning off the light source. Current 
traces were fitted with a mono-exponential function. The time constant t amounted to 
(1.1 ± 0.4) s (mean ± SD, n = 7) for the trans-to-cis transition and (2.0 ± 0.7) s (mean ± 
SD, n = 6) for the cis to trans transition.  
Next, we investigated anesthetic activity and photoreversibility of both propofol 
and AP2 in a small animal model, albino Xenopus laevis tadpoles. Groups of animals 
were placed in aqueous solutions containing either propofol or AP2 and tested every 
five minutes for loss of righting reflexes (LORR), a standard assay for anesthesia.[13] 
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Figure 24. a) α1β2γ2 GABAA receptors 
were expressed in Xenopus oocytes. 
Currents were activated with a concen-
tration of GABA eliciting 0.3% of the max-
imal current amplitude (EC 0.3) with in-
creasing amounts of either propofol or 
AP2. Mean ± SEM of four experiments is 
shown. b) GABA (1µM) was applied re-
petitively until a stable current response 
was observed. Co-application of AP2 (1.5 
µM) with GABA resulted in current poten-
tiation. During co-application, the oocytes 
was exposed to a light source emanating 
390-450 nm light. As a consequence, 
current stimulation rapidly decreased 
until it reached a steady level. When the 
light-source was turned off, the amplitude 
increased again. This procedure was 
repeated. This experiment was repeated 
independently six times using different 
oocytes. c) α1β2γ2 GABAA receptors were 
expressed in HEK cells.  GABA (0.5 µM) 
was co-applied with AP2 (5 µM). Subse-
quently, the perfusion was stopped and 
the cells were exposed to the light 
source. The inward current amplitude 
decreased rapidly and increased again 
upon turning off the light source (trace 
left). Current decrease (trace top right) 
  
 
 
 59 
Steady-state LORR results were observed at 10 min for propofol and 25 min for 
AP2. After 30 min in drug solution, each animal was exposed for five to ten seconds to 
360–370 nm bandpass filtered UV light (details in the Supporting Information) while 
retesting for LORR. Propofol alone produced LORR with an EC50 of 1.3 µM (Figure 
25a). 
Illumination induced vigorous swimming activity in unanesthetized tadpoles 
(thus suggesting that illumination represents a noxious stimulus) and a small rightward 
shift in the corresponding plot of LORR versus propofol concentration was observed 
(EC50 ca. 2.0 µM ; Figure 25a). AP2 alone produced LORR with an EC50 value similar 
to that of propofol (1.1 µM ; Figure 25b). However, illumination produced a large right-
ward shift in the AP2 EC50 value to 4.6 µM (Figure 25b).  
 
 
 
Figure 25. Light-dependent anesthesia in tadpoles. Loss of righting reflexes is plot-
ted against aqueous anesthetic concentration, overlayed with logistic fits. Each point 
represents data from ten animals. a) 360– 370 nm light, an apparently noxious stimulus 
in Xenopus tadpoles, produces a small rightward shift in propofol-dependent loss of 
righting reflexes (LORR) from (1.1 ± 0.1) µM (circles) to (2.0 ± 0.1) µM (stars). b) 360–
370 nm light shifts the AP2-dependent LORR curve to the right from (1.1 ± 0.1) µM 
(squares) to 4.6 ± 0.2 µM (crosses). This larger shift is due to photoisomerization of 
AP2. 
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All animals recovered from anesthesia when returned to water alone. In an in-
dependent set of experiments (see video in the Supporting Information), propofol (3 
µM) produced LORR in all tadpoles with or without light, whereas in AP2 (3 µM), all 
animals showed LORR without light and all spontanously righted themselves and 
swam during illumination with UV light. 
The photoreversibility of both AP2-induced GABAA receptor modulation and its 
anesthetic action in animals supports the hypothesis that anesthesia caused by AP2 
and propofol is largely mediated by GABAA receptors. However, evidence also impli-
cates other targets, including HCN1 channels (hyperpolarization-activated cation chan-
nels),[18] in propofol’s anesthetic actions. The examination of the effects of AP2 on the-
se other targets and the investigation of the photoreversibility of the modulation of the-
se targets might help to further elucidate their roles in the pharmacology of general 
anesthesia. 
 
Conclusion 
In summary, we have developed photoswitchable versions of propofol that allow 
the indirect optical control of GABAA receptors. Functionally, our compounds differ from 
previously introduced PCLs, because they act as photochromic potentiators rather than 
photochromic agonists, antagonists, or channel blockers. Application of our lead com-
pound, AP2, in the dark potentiates GABA-induced Cl- currents, which can be reversed 
upon irradiation with violet light. The ability of azo-propofols to control neural systems 
has been demonstrated, since AP2 functions as a light-dependent anesthetic in trans-
lucent tadpoles. Future work will address the usefulness of azo-propofols in other sys-
tems, such as brain slices and retinas lacking innate photoreceptors, wherein photo-
chromic potentiators could restore visual responses through their action on neurons 
expressing GABAA receptors. 
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3 Discussion and Outlook 
3.1 A novel insecticide? 
We identified an aromatic monovalent anion with five-fold symmetry (PCCP-) as 
an inhibitor of rat α1β2γ2 GABAA receptors. Our work should be compared to other re-
ports on non-competitive inhibitors of the GABAA receptor. Studies carried out with 
negatively charged sulphated steroids, such as pregnenolone sulphate showed an un-
competitive inhibition of the GABAA receptor-mediated current (Shen et al., 2000; Ei-
senman et al., 2003) through steady-state allosteric effects (Shen et al., 2000; Akk et 
al., 2001; Eisenman et al., 2003). Interestingly, pregnenolone sulphate (PS) antago-
nism was dramatically reduced by mutation in the M2 residue V256 of the α1 subunit 
while the homologous mutations of the β2 subunit (A252S) or the γ2L subunit (S266A) 
had no effect. Therefore the authors implied that α1V256 is involved in a conformational 
change underlying block by pregnenolone sulphate, instead of forming part of the bind-
ing site for PS (Akk et al., 2001). Another study reported that hydrophobic anions, as 
dipicrylamine (DPA), unrelated to neurosteroids strongly antagonize GABAA receptor 
function in the same manner as PS (Chisari et al., 2011), including sensitivity to the 
V256 point mutation in the M2 of the α1 subunit. As this uncompetitive and membrane-
potential independent inhibition is shared by a wide variety of hydrophobic anions and 
amphipatic compounds (Chisari et al., 2010) and at sufficiently high concentrations, 
even uncharged neurosteroids exhibit this mechanism (Wang et al., 2002) the authors 
suggested that the potent antagonism of channel function by these different com-
pounds was due to a possible plasma membrane modification that also leads to a 
change in membrane capacitance (Chisari et al., 2011; Mennerick et al., 2008). While 
these agents are hypothesized to act in an allosteric fashion we have strong evidence 
for a direct action of PCCP- on the transmembrane segment M2 of GABAA receptors. 
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 PCCP- induces open-channel block, characterized by an apparent desensi-
tization of the current and an off-current. As expected this block becomes more promi-
nent with increasing agonist concentrations. Interestingly, the block is voltage-
dependent indicating an action in the inner leaflet of the membrane. Action of PCCP- is 
not affected by the substitution of the β2 subunit with β1 or by the presence of δ subunit. 
We identified, through a mutation scan, several amino acid residues involved in the 
formation of the binding between PCCP- and GABAA receptor. The cysteine mutants 
α1V256Cβ1γ2 and α1T261Cβ1γ2 both showed 30-20 fold decrease in the apparent affini-
ty of PCCP- to inhibit currents elicited by GABA. To validate our finding we also used 
the substituted-cysteine-accessibility method where a positively charged reagent 
MTSET+ reacts covalently with the cysteine residues of the mutated subunits (Akabas 
et al., 1992, 1994). Covalent reaction of MTSET+ was prevented in the presence of 
PCCP-. The effect of PCCP- was potentiated after treatment with the cysteine reactive 
reagent MTSET+. The introduction of two positive charges (one for each of the α subu-
nits) by MTSET+ compound, may favour the interaction of the channel with the nega-
tively charged PCCP- and this is possible only if PCCP- enters the channel. Similar 
studies on the open channel blocker picrotoxin indicated a possible interaction between 
picrotoxin and α1V256 and α1T261 both facing the lumen of the channel, although the 
authors could not exclude a possible allosteric interaction through another binding site 
outside of the lumen (Xu et al., 1995). The crystal structure of the homo-pentameric 
Caenorhabditis elegans glutamate-gated chloride channel showed that picrotoxin di-
rectly occludes the chloride channel at positions corresponding to P252 and V256 in 
the M2 of the the rat α1 receptor subunit (Hibbs et al., 2011). Our data indicate that 
PCCP-, acts one turn of the α−helix shifted into M2 as compared with to picrotoxin. All 
crystallized cys-loop receptors have a predicted lumen diameter significantly smaller 
than open channel blockers. How can PCCP- with a diameter of approximately 10Å sit 
  
 
 
 66 
into the channel? As indicated above the GluCL channel crystallized in the presence of 
picrotoxin shows picrotoxin at the 2’ position (0' position at the predicted membrane 
surface), where the diameter measures 4.6 Å (Hibbs et al., 2011). This may be ex-
plained by the fact that the surface of the channel is not smooth and very flexible. We 
think that PCCP- binds between the 2’ and 6’ position by plugging the pore in a parallel 
position to the lipid bilayer due to the H bonds formed with the hydroxy groups of the 
highly conserved 6’ α1T260C and at 2’ α1V256C. The predicted diameter in all crystal-
lized cys-loop receptors is in that position is 6-9 Å. A location of the binding site in the 
inner leaflet is also predicted by the membrane potential dependence of the block by 
PCCP-. In insect GABAA receptors RDL a point mutation of the Ala302 to Ser (homolo-
gous to rat α1V256) conferred resistance to picrotoxin (Hosie et al., 1995). Interestingly, 
PCCP- inhibits these mutated channels indicating a potential use as insecticide. Chem-
ical modification of the PCCP- structure will hopefully result in higher affinity inhibitors  
A collaboration with a company resulted in promising observations in insects. The col-
laboration came to a halt as we were forced to publish our data. 
3.2 Photopharmacology  
In a second study we characterised a light-switchable modulator of GABAA re-
ceptors. While GABAA receptors respond to a variety of ligands, they are normally not 
sensitive toward light. This light sensitivity could be indirectly achieved by using ligands 
that act on the receptors but can be optically switched between an active and an inac-
tive form. We tested an azobenzene derivative of propofol where an aryldiazene unit is 
directly coupled to the pharmacophor. This molecule is termed azopropofol (AP2). 
First, we compared the relative effect of propofol and AP2 on the GABAA receptor in 
the dark to compare the relative effects. AP2 in its dark-adapted trans form has a sig-
nificantly higher affinity than propofol itself, which its efficacy is reduced by about two 
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fold. Due to redistribution of the hydrophobic compound AP2 into egg yolk, the rate of 
photo-switching could not be determined in Xenopus oocytes. For this purpose, we 
studied the switching kinetics in patch clamp experiments using the whole-cell patch 
clamp technique. The current amplitude decreased rapidly and increased again upon 
turning off the light-source allowing an optical control of the GABAA receptors.  
In the past optogenetic manipulations have been used to dissect neuronal func-
tions. These manipulations included expression in neuronal tissue of photosensitive ion 
channels. Photopharmacology avoids genetic manipulation and adaptive phenomena 
observed after expression of a new gene. AP2 may be employed in brain tissue slices 
where one could selectively irradiate neurons or even single synapses with high tem-
poral resolution. Furthermore, there might be a potential application in human brain 
surgery. It might be possible relieve narcosis locally by irradiation of part of the motor 
cortex and test e.g. motility properties of the patient. 
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4 Additional project: GABA in liver 
4.1 Introduction 
As described in chapter 1, GABAA receptors are also found in a wide range of 
peripheral tissues, including liver and several cancer tissues. However their precise 
function in non neuronal cells is in many cases still unknown.  
The liver is the body's largest single organ. It has four major functions: metabo-
lism and synthesis, excretion, storage, and the detoxification of potential poisons. 
Sympathetic, parasympathetic and peptidergic fibers are responsible for the liver inner-
vation. In the human liver, nerve endings are located in the hepatic lobules (Ueno et al., 
2004), which consist of hepatocytes and non-parenchymal cells. Hepatocytes occupy 
80% of the liver mass, parenchima cells occupy only about 6.5%. Hepatocytes are ar-
ranged as cellular cords with a radial disposition that converges towards the centrilobu-
lar vein, being separated by sinusoidal capillaries. Between hepatocyte cell cords and 
sinusoid capillaries there is an interstitial space, a perisinusoidal called a Disse space. 
This space is formed by a fine network of reticulin fibers, a support for the sinusoids, 
non myelinated nerve fibers and mesenchymal type cells (Crişan and Mureşan, 2004). 
Most hepatocytes are not directly innervated but there is an indirect mechanism for 
transmitting nervous inflow. One such mechanism is the intercellular communication 
carried out between adjacent hepatocytes via specific channels known as gap type 
junctions (GJ), which allow the passage of ions and small molecules (Shimazu, 1996). 
Hepatocytes are multifunctional epithelial cells, with the main functions to regulate 
trans-cellular solute transport, processing of metabolites and synthesize and export of 
numerous important proteins. During liver regeneration, hepatocytes initiate cell prolif-
eration, maintain metabolic function of the liver, secrete interleukin-6 (IL-6), proteases, 
protease inhibitors and hepatocyte growth factor (Zheng et al., 2009). Many functions 
are carried out by anion channels. For example a chloride channel, which belong to the 
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CLIC channel family is important in cell volume regulation, in the control of membrane 
potential and trans-cellular transport of hepatocytes (Graf and Haussinger, 1996). The 
presence chloride channels correlates to the membrane potential of -30 to -40 mV 
(Moule and McGivan, 1990).   
The GABAA receptor seems to be expressed in hepatocytes. Specifically, ex-
pression of β3 and ε GABAA receptor subunits has been described. β3 subunit down-
regulation in hepatocytes has also been associated with a decrease of the hepatocyte 
membrane potential and an increase of the cell proliferation. In particular, the β3 subu-
nit is down-regulated in liver carcinoma. Carcinoma cell lines transfected with β3 have 
been reported to be less aggressive in vivo than non transfected cells (Sun et al., 2002; 
Minuk et al., 2007).  
We planned to investigate the expression and function of the hepatocyte 
GABAA receptor in a model system (immortalized human hepatocytes) and healthy and 
cancerous primary hepatocytes. Additionally, we were interested in the localization in 
healthy human tissue.  
4.2 Materials and Methods 
Material. The immortalized human hepatocyte cell line (IHH) (Nguyen et al., 
2005) was kindly provided by Dr. J.F. Dufour; primary hepatocytes and liver tissues 
were obtained from Dr. D. Stroka. A mouse monoclonal antibody bd17, specific for 
β2/β3 subunit was kindly provided by Hoffmann-La Roche; the polyclonal rabbit anti-
body (AP2789c) against the human β3 GABAA receptor subunit was from ABGENT 
(San Diego, CA 92124), a mouse monoclonal antibody (AB98968) specific for the ami-
no acids 370-433 of human β3 GABAA receptor subunit was from ABCAM (Cambridge, 
UK), the mouse monoclonal against Actin protein (sc-69879) was from Santa Cruz Bio-
technology (Texas, USA), a rabbit polyclonal antibody against ε  protein was purchased 
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by Aviva system Biology, the rabbit polyclonal against MRP2 protein (4446) and the 
rabbit monoclonal antibody against E-Cadherine (3195) were from Cell Signaling (All-
schwil, Switzerland). 
Cell culture. The immortalized human hepatocytes were grown in Dulbeco's 
minimum essential medium F12 (Life technology, Zug, Switzerland) supplemented with 
10% heat-inactivated fetal bovine serum, 50 U/ml penicillin, 50 µg/ml streptomycin, and 
50 mg/mL Gentamycin, 10 mg/mL Insulin-transferrin-selenite and 2mg/mL Dexame-
thasone in a humidified, 37°C incubator in an atmosphere of 95% air-5% CO2. Primary 
human hepatocytes were isolated from the resected liver tissue of consented patients 
undergoing liver surgery. Human hepatocytes were enzymatically dissociated from 
human liver samples using a two-step enzymatic microperfusion technique with colla-
genase and kept on ice in suspension (Strain, 1994). Hepatocytes were subsequently 
seeded in plastic dishes coated with rat-tail collagen (25 µg/cm2) at a density of 
130,000 viable cells/cm2 and cultured in Dulbeco's minimum essential medium sup-
plemented with 10% heat-inactivated fetal bovine serum, 50 U/ml penicillin, 50 µg/ml 
streptomycin, and 1 µM dexamethasone. After overnight culture, the medium was re-
placed by serum-free Williams' E medium supplemented with 100 nM hydrocortisone, 
50 U/ml penicillin, 50 µg/ml streptomycin, and solution ITS + 1, containing insulin (5 
µg/ml), transferrin (2.75 µg/ml), and selenium (25 ng/ml) (Sigma, Buchs, Switzerland). 
The medium also was supplemented with 250 µg/ml bovine serum albumin and 2.35 
µg/ml linoleic acid. In the following days after serum deprivation, the human hepato-
cytes were kept in serum-free medium and harvested at different time points for protein 
and electrophysiological analysis. 
RT-PCR and qPCR for detection of GABAA receptors subunits. Total RNA 
was extracted from 20%, 40%, 60%, 80% cell confluence, by the commercially availa-
ble TRIZOL method (Invitrogen, Carlsbad, CA). To determine quality and integrity of 
the RNA the ratios of the absorption at 280 and 260 nm was determined; RNA was 
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stored at -80° C until further analysis. Reverse transcription of 1 µg RNA was per-
formed with random hexamer primers using the Applied Biosystems (Zug, Switzerland) 
reverse transcription kit according to the manufacturer’s instructions.  
 
TABLE 2. Gene-specific PCR and qPCR primers for Human GABAA receptor sub-
units 
Species / 
Gene Sequence [5'-3'] Accession number 
    Anneling 
 temperature (°C)1 
       Fragment  
lenght [bp] 
Homo Sapiens     
α1 TCGTCACCAGTTTCGGACC NM_000806.5 58 902 
 GGTTGCTGTTGGAGCGTAA    
α2 TTCACAATGGGAAGAAATCAGTAG XM_006714002.1 60 722 
 TGCATAAGCGTTGTTCTGTATCA    
α3  GGAAGTGGCACAGGATGGTTC NM_000808.3 60 658 
 GTTGTAGGTCTTGGTCTCAGTCGG    
α4 TGAAATTCGGGAGTTATGCCTATC NM_000809.3 60 750 
 GGCTGAATGGGTTTGGACTG    
α5 CACCATGCGCTTGACCATCTCT NM_000810.3 60 826 
 GCCGAACAAGACTGGGAATA    
α6 TGAGGCTTACCATCAATGCTGA NM_000811.2 60 764 
 GACAGGTGTTGATTGTAAGATGGG    
β1  GTTCTCTATGGACTCCGAATCACA NM_000812.3 60 603 
 ATTGGCACTCTGGTCTTGTTTG    
β2 AGCTTAAGAGAAACATTGGCTACT NM_000813.2 58 643 
 CGATCTATGGCATTCACATCA    
β3   ATGGGCTCAGAATCACCA NM_000814.5 58 250 
 GATAGGCACCTGTGGCGA    
γ1  GTGTTTTGCAGCCTTGATGG NM_173536.3 58 284 
γ2 
TGGCAATGCGTATGTGTATCCT 
AAGTCCTCCGATTGAACAGCAACA NM_000816.3 60 605 
 CGCTGTGACATAGGAGACCTT    
γ3 ACACTCCTGCCCGCTGATT XM_006724812.1 58 767 
 TGTCTATGTGAATACGCCCTTTCC    
δ   TCACCATCACCAGCTACCACTTCA NM_000815.4 58 654 
 GGGCGTAAATGTCAATGGTGTC    
ε qPCR CTCTCGCATCCTGAACACTATCC NM_004961.3 60 104 
 GGCTGTTGACGGAGATCTCAA    
β3 qPCR GACAAGGCTGTTACCGGAGT NM_000814.5 60 127 
 
CGAAAGCTCAGTGACAGTCG 
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The oligonucleotide primers for the RT-PCR and qRT-PCR were designed 
against human GABAA receptor sequences by using Oligo 4.0. The sequences of the 
human GABAA receptor subunits oligonucleotide primers are show in the Table 2.  
The RT-PCR amplification was carried out in 35 cycles of denaturation at (92°C, 
12 sec), anneling (55°C, 15 sec), and elongation (68°C, 1min) and with an additional 2 
min final extension at 72°C. Finally 10 µl of the PCR products were run on 2% agarose 
gels. qRT-PCR was performed using Power SYBR Green Master Mix (Promega, Fos-
ter City, CA, USA) in a final volume of 25 µl and a final primer concentration of 150 nM. 
qRT-PCR were carried out on a ABI Prism 7500 real-time PCR detection system (Ap-
plied Biosystems). For each gene a standard curve was generated using a plasmid 
containing β3 cDNA or ε cDNA to determine detection limits and efficiencies for each 
primer pair. Amplified products underwent melting curve analysis to specify the integrity 
of amplification. To remove non-specific signals, a higher fluorescence acquisition tem-
perature was chosen (Table 2), according to the melting curve that was recorded for 
each reaction. In all studies, the arithmetic mean of the CT values (the cycle number at 
which logarithmic plots cross calculated threshold lines) of β−actin, was used to nor-
malize the abundance of target mRNA to that of total mRNA. Calculations were done 
using the software KaleidaGraph. 
SDS-gel electrophoresis and immunoblotting techniques. Cells were har-
vested by scraping into a protease inhibitor mixture consisting of (in mM) 10 HEPES, 3 
EGTA, 1 PMSF, 10µL Protease Inhibitor Cocktail solution (Sigma, Buchs, Switzerland). 
Protein concentrations were measured by using the BCA protein assay (Thermo Scien-
tific). Total protein extracts (10 µg) were separated on 10% polyacrylamide-SDS gels 
and electroblotted to nitrocellulose membranes. Membranes were blocked with 5% 
skim milk in Tris buffered saline (0.02M Tris base pH 7.6) for 1h at room temperature 
and incubated with the rabbit anti-human GABAA-β3/β2 50 µg/ml (bd17) receptor anti-
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body or the monoclonal mouse anti-human GABAA-β3 1 µg/ml (AB98968), overnight at 
4°C. Bands were detected with a horseradish peroxidase labeled secondary antibody 
(anti mouse P0260, Dako, 1:1000 and the anti rabbit W401B, Promega, 1:20000) cata-
lysed chemiluminescence reaction (Thermo Scientific, Switzerland). Controls included 
calf brain membrane protein and protein from the HEK cells (American Type of Culture 
Collection, MD, USA, CRL 1573) transfected with β3 GABAA subunit cDNA using the 
calcium phosphate precipitation technique (Chen and Okayama 1987). 
Immunohystochemistry. Human liver samples from tumour-free resection 
margins or non-tumor liver were obtained already embedded in Tissue –TekTM Cryo 
OCT from Dr. Deborah Stroka. Tissue was cut into 6 µm sections with Leica Microtome 
and fixed for 5 min with 4% paraformaldehyde, then the slides could be frozen at -20°C 
until further use. Sections were blocked with 0.2 M glycine for 5 min and then blocked 
with 5% normal goat serum /0.05% Casein/PBS-Tween20 (PBST) for 1h. Primary anti-
body (mouse monoclonal 1:1000 and rabbit polyclonal anti-β3 1:10, anti- E-Caderine 
1:50, anti-MRP2 1:200) in blocking solution were incubated overnight at 4°C. Sections 
were washed 3x times in 1X Phosphate Buffered Saline Tween-20 (PBST). The sec-
ondary antibody (Alexa Fluor® 488 and 594 conjugated goat anti-rabbit polyclonal sec-
ondary antibody 1:1000) were incubated for 1h at RT in blocking solution. Sections 
were mounted with Eukitt (Kindler, GmbH). The signals were detected with a confocal 
microscope (Olympus).  
Electrophysiology. The whole-cell patch-clamp technique was used to record 
currents activated by GABA (10 µM) from IHH cells voltage-clamped at 0 mV. GABA 
was applied using a perfusion system consisting of glass reservoir connected to a 
Warner Perfusion solenoid mini valve control system (Harvard Apparatus). The record-
ing chamber was continuously perfused (5 ml/min) with an extracellular solution com-
prized of (in mM) NaCl, 146; KCl, 5; MgCl2, 4; CaCl2, 1; glucose, 5; and HEPES–
NaOH, 10 (pH 7.4). The electrode solution contained (in mM): Cs Methyl sulfonate, 
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125; MgCl2, 2; EGTA, 0.5; ATP (Mg2+ salt) 2; and HEPES–CsOH, 10 (pH 7.4). Experi-
ments were performed at room temperature (20–24 °C).  The gap junction blocker Oc-
tanol (1 mM) (Contreras et al., 2002) obtained from Sigma (St. Louis, MO) was added 
to the extracellular solution. This combination of external and internal solution produced 
a chloride equilibrium potential of -60 mV. Measurements were performed using an 
EPC-10 amplifier (HEKA, Lambrecht/Pfalz, Germany). The currents filtered with a 0.1 
kHz Bessel filter and sampled at 0.5 kHz. 
4.3 Results 
mRNA expression. mRNA expression was investigated in the immortalized 
human hepatocyte cell line (IHH) (Nguyen et al., 2005) in three different  independent 
total RNA isolations to see if these cells present a similar expression pattern of GABAA 
receptor subunits as healthy hepatocytes. The results of the end point RT-PCR in IHH 
cells showed the presence of α3, β3, β2, ε GABAA receptor subunits (Figure 26). 
 
Figure 26.  GABAA receptor subunit isoform mRNA expression in three RNA iso-
lations from IHH cells at 100% confluency. The experiment was carried out three 
additional times with similar results. 
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As it has been reported that expression of β3 inversely correlates rate of with 
cell division, we investigated whether β3 and ε GABAA receptor subunits expression 
correlates with the degree of confluency. mRNA abundance was measured by real time 
qPCR in IHH cell at 40% confluence corresponding to dividing cells and 100% corre-
sponding to non dividing cells. Relative mRNA levels of β3 and ε were similar at 40% 
confluency and at 100% confluency (Figure 27). 
 
 
Figure 27.  (A-B) qPCR analysis of ε  and β 3and GABAA receptor subunits in IHH 
cells at 100% and 50% confluency.  
4.3.1 Protein expression.  
At the protein level β3 subunits were detected in IHH cells using two different an-
tibodies for β3: a mouse monoclonal antibody bd17, specific for β2/β3 subunit and a 
mouse monoclonal antibody AB98968, specific for the amino acids 370-433 of human 
β3 GABAA receptor subunit.  The specificity of the antibodies was confirmed by Western 
Blot analysis of lysates of COS-7 cells transfected with recombinant β3 subunit. All an-
tibodies described above recognized a band of 55KDa that was specific for the trans-
fected cells (Figure 28). 
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Protein extracts from both liver tissue and IHH cells showed a band of 55KDa 
using both bd17 and AB98968 antibodies (Figure 29). 
 
 
 
To investigate whether β3 protein expression in IHH cells correlates with prolif-
eration, cell lysates were harvested at 4 different degrees of confluency (40%, 70%, 
90% and 100%) and analysed by Western Blot.  
The protein abundance was quantified by densitometric image analysis of the 
blots. In 40% confluent cells, β3 protein levels amounted to approximately 20% as com-
pared to the over-confluent cells, (Figure 30). 
In order to demonstrate ε subunit expression, we used a rabbit polyclonal anti-
body against ε protein. We observed a band of 57KDa in IHH cell, primary hepatocytes 
and liver tissue (Figure 31). 
96 
72 
52 
42 
Figure 28. Western blot analysis in COS7 cells 
transfected with β3 plasmid to check the antibo-
dy specificity for β3 GABAA receptor subunit pro-
tein expression. 
Figure 29. Protein expression of β3 
in IHH cells and liver tissue. 
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Figure 30. Expression levels of the β3 subunit were determined by western blot 
analysis in IHH cells grown  at different degree of confluency: 40%, 70%, 90% 
and overconfluent. In all the samples the same amount of protein was loaded. Detec-
tion of Actin served as a loading control (A). The protein abundance was quantified by 
image analysis of the blots.  Band intensity was normalized tot he overconfluent values. 
The β3 subunit is downregulated in 40% confluent cells as compared with overconfluent 
cells. Data are given as mean ±  SEM (6 independent experiments). 
 
 
Figure 31. Protein expression of  ε  subunit in IHH cells and liver tissue 
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4.3.2 Localization (Immunohistochemistry)  
We localized the β3 subunit in healthy freshly frozen liver tissues using immuno-
fluorescence on a confocal microscope. We used two antibodies specific for β3: mono-
clonal mouse antibody (AB98968) and polyclonal rabbit antibody (AP2789c). Both anti-
bodies showed a basolateral membrane staining for β3 subunit in healthy liver tissue. 
Double labelling with apical markers, an antibody specific for the multidrug resistance 
protein (MRP) 2 showed a precise complementary apical staining with β3 basolateral 
staining. (Figure 32). The commercial antibody specific for ε subunit used in western 
blot failed to stain the antigen in immunohistochemical sections. 
 
Figure 32. Presence of β3 GABAA receptor subunit in liver tissue. (A-D) Im-
munostaining for β3 GABAA receptor subunit is shown in green. (B-E) the apical marker 
MRP2 is shown in red. The image pairs A-B and D-F are superimposed in (C) and (F). 
The experiment was carried out three additional times with similar results. 
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4.3.3 Electrophysiology: patch clamp technique.  
We tried to apply the patch clamp technique to IHH cells with the aim to deter-
mine the functional properties of the expressed GABAA receptors. Measurements was 
extremely difficult due to the tendency of the IHH cells to swell. Unfortunately the prom-
ised human primary hepatocytes did not became available for electrophysiological 
analysis.  Exposure of IHH cells to 100 µM GABA did often not result in any currents. 
Figure 33 shows an exception with an outword current of about 80 nA. 
 
 
 
4.4  Discussion  
Some observations prompted us to study the role of GABAA receptors in liver. 
Minuk et al. (2007) described that GABA inhibits the proliferation of the HepG2 human 
hepatoblastoma cell line and expression of β3 and ε GABAA receptor subunits in 
hepatocytes (Minuk et al., 2007). β3 (mRNA and protein) was found to be downregulat-
ed in liver carcinoma (Minuk et al., 2007). Carcinoma cell lines transfected with β3 were 
found to be less aggressive in vivo than non transfected cells (Minuk et al., 2007). β3 
subunit down-regulation was also paralleled by a decrease of the hepatocyte mem-
brane potential and an increase of the cell proliferation. Later studies have shown that 
Figure 33. Current measurement in whole cell 
mode in 100% confluent IHH cells held at 0 mV 
during treatment with GABA (100 µM). The intra-
cellular solution contained 15 mM Cl-; extracellular 
solution contained 155 mM Cl-. GABAA receptor was 
activated by bath application of 100 µM GABA. An 
outward current of about 80pA was elicited. 
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GABA inhibited human liver cancer cell migration and invasion via the ionotropic 
GABAA receptor (treatment with GABAA receptor agonists (T101), but not with GABAB 
receptor agonists (Baclofen) showed the specific action through the GABAA receptor) 
as a result of the induction of liver cancer cell cytoskeletal reorganization (Chen et al., 
2012). Pre-treatment with GABA also significantly reduced intrahepatic liver metastasis 
and primary tumour formation in vivo (Chen et al., 2012). However, the precise role of 
GABA and its receptors in human liver cancer cell migration and invasion is not well 
understood. Specifically, no GABAA receptor activity had ever been shown. 
We chose the immortalized human hepatocyte (IHH) as a model system for fur-
ther studies. There is evidence that the plasma cell membrane potential influences cell 
proliferation (Morokuma et al., 2008; Sundelacruz et al., 2009) Depolarization of em-
bryonic cells by mis-expression of a certain type of potassium channels (KCNE1) in-
duced melanocytes to over-proliferate, spread out, and become highly invasive of 
blood vessels, liver, gut, and neural tube. (Morokuma et al., 2008). Factors, such as 
neurotransmitters, that change the membrane potential contribute to the control of cell 
proliferation (Martins and Pearson 2008). The neurotransmitters GABA, has been 
shown to regulate proliferation of several cell types apart of liver cancer cells, including 
embryonic stem cells (Andäng et al., 2008), immune cells, (Jin et al., 2013, Bjurstom et 
al., 2008). 
 mRNA and protein expression in IHH cells. The mRNA profiles of GABAA 
receptor subunits β3 and ε were investigated with different degrees of confluency in IHH 
cells (40%, 70%, 90% and 100%). Neither β3 nor ε mRNA showed significant differ-
ences when the cells were 40% or 100% confluent. In vitro studies showed that β3 can 
form a functional homomeric receptor upon expression in canine kidney cells (MDCK) 
(Connolly et al., 1996). Studies in oocytes showed the formation of functional receptor 
from ε, β2 and α1 GABAA receptor subunits (Bollan et al., 2008). We need additional 
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studies to investigate the possible subunit combination expressed in hepatocytes. At 
the protein level, we found an inverse correlation between β3 protein expression and 
degree of proliferation. As this correlation was observed at the protein level but not the 
mRNA level our findings suggest a post-transcriptional regulation. Our results are in 
line with earlier findings (Minuk et al., 2007).  
Subcellular localization of β3 subunit. We investigated the localization of β3 
GABA receptor subunit in healthy liver tissue and found a basolateral localization for 
the β3 subunit protein. The apical surfaces in liver cells are exposed to bile cannaliculi 
and basolateral surfaces are in contact with the blood (Figure 34).  
 
 
 
 
Adjacent epithelial cells are connected by tight junctions. This organization permits 
regulated import of substances into the body as well as export of substances from the 
body (Duffield et al, 2008; Mellman and Nelson, 2008; Martin-Belmonte and Mostov, 
2008; Müller and Bossinger, 2003). Similarly neurons show a polarized morphology in 
which they usually have a single axon and multiple dendrites originating from the cell 
body. The axon (apical) from one cell releases the neurotransmitter which will bind a 
receptor located on the dendrites (basolateral) of a different cell at the synaptic cleft. 
The polarity of the neuron thus facilitates the directional flow of information, which is 
required for communication between neurons and effector cells. 
Figure 34. Cell polarization in 
normal epithelial cells and 
hepatocytes. 
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A study in MDCK cells showed specific basolateral targeting of both α1β2 and 
α1β3 GABAA receptors. Interestingly, delivery of receptors containing the β3 subunit to 
the basolateral domain occurs via the apical surface. These results showed that beta 
subunits can selectively target GABAA receptors to distinct cellular locations (Connolly 
et al., 1996). GABAA receptors localized in the basolateral membrane of hepatocytes 
would bind the GABA neurotransmitter in the plasma. It has been show that the GABA 
concentration in the blood is around 100 nM (Petty, 1994). Interestingly, the betaine 
GABA transporter (BGT1) (protein and mRNA) and the GABA transporter type 2 
(GAT2) were found to be expressed in rat hepatocytes and targeted to the sinusoidal 
plasma membranes facing blood plasma (Zhou et al., 2012). Therefore hepatocytes 
are equipped to take up GABA from the plasma and a use for activation GABA recep-
tors in the basolateral membrane cannot be excluded. 
Electrophysiology. To investigate whether Isubunit  express a functional 
GABAA receptor, we conducted electrophysiological studies. As mentioned above the 
studies were technically difficult, unfortunately we were not able to obtain reproducible 
results. One of the main problems was the swelling of the cells after clamping. Swelling 
is a well studied characteristic of the hepatocytes, which is correlated with the presence 
of chloride channels. GABAA receptors form also a chloride channels. It cannot be ex-
cluded that GABAA receptor is involved in controlling the swelling. As IHH cells are not 
polarized it is possible that no functional GABAA receptors are expressed. The few 
times we obtained primary hepatocytes for electrophysiological recording, their quality 
did not allow electrophysiological experiments.  
4.5 Outlook 
Localization. It will be interesting to localize β3 subunit in liver cancer tissue 
and IHH cells. To localize the β3 subunit in IHH cells a collagen sandwich cell culture 
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model could be established allowing three-dimensional differentiation (Tuschl et al 
2009). Furthermore, after the interesting observation of the presence of the BGT1 and 
GAT2 GABA transporters in the liver we need to understand if these transporters are 
really involved in GABA transfer from the blood to the hepatocytes and if it regulates 
the expression of GABAA receptors in the membrane in physiological or pathological 
condition such as cancer, where β3 subunit is known to be down-regulated (Minuk et 
all, 2007), or if, for example BGT1 is only involved in the Betaine transport as previous-
ly described (Zhou Y, et al; 2011). It will be interesting to see if also the BGT1 and 
GAT2 protein expression is varying with the degree of confluency in IHH cells. In addi-
tion, it could be studied if GABAA receptor expression is affected in the liver of mice 
lacking of the BGT1 protein  
Function. The most important aim of my project was to look for GABAA recep-
tor function. Unfortunately, nobody has been able so far to achieve this. Electrophysio-
logical studies with other hepatocyte cell lines or native hepatocytes may overcome the 
technical limitations we observed using IHH cells. 
Hepatocyte proliferation. Western Blot analysis of the β3 subunits showed a 5-
fold increase in β3 protein level with increasing confluency of the cells. This suggests 
that hepatocytes might only express GABAA receptors when “sensing” other hepato-
cytes and increase production of the receptors as confluency increases. Additional 
studies with siRNA directed against β3 and ε GABAA receptor subunits will lead to the 
better understanding of the role of GABAA receptor in proliferation of the hepatocytes. 
siRNA approches have successfully been used in hepatocyte cell lines (Shan et al., 
2004)., When the hepatocytes start to be connected with each other, a swelling is ob-
served, due to a Cl- conductance. It will be interesting to understand if GABA is also 
involved in controlling the swelling or the osmolarity of the cells to optimize the contact 
with other cells.  
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